<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6030256</article-id><article-id pub-id-type="pmcid-ver">PMC6030256.1</article-id><article-id pub-id-type="pmcaid">6030256</article-id><article-id pub-id-type="pmcaiid">6030256</article-id><article-id pub-id-type="pmid">29997628</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.01484</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gornati</surname><given-names initials="L">Laura</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/562097"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zanoni</surname><given-names initials="I">Ivan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/34335"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Granucci</surname><given-names initials="F">Francesca</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="fn001">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/29919"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biotechnology and Biosciences, University of Milano-Bicocca</institution>, <addr-line>Milan</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>Division of Gastroenterology, Harvard Medical School, Boston Children&#8217;s Hospital</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Piergiuseppe De Berardinis, Istituto di biochimica delle proteine (IBP), Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Raffaele De Palma, Universit&#224; degli Studi della Campania &#8220;Luigi Vanvitelli&#8221; Caserta, Italy; Federica Moschella, Istituto Superiore di Sanit&#224;, Italy; Antonio Leonardi, Universit&#224; degli Studi di Napoli Federico II, Italy</p></fn><corresp id="fn001">*Correspondence: Francesca Granucci, <email>francesca.granucci@unimib.it</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">305241</issue-id><elocation-id>1484</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2018</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>11</day><month>07</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-22 16:25:17.840"><day>22</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2018 Gornati, Zanoni and Granucci.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Gornati, Zanoni and Granucci</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-09-01484.pdf"/><abstract><p>Vaccines represent the discovery of utmost importance for global health, due to both prophylactic action to prevent infections and therapeutic intervention in neoplastic diseases. Despite this, current vaccination strategies need to be refined to successfully generate robust protective antigen-specific memory immune responses. To address this issue, one possibility is to exploit the high efficiency of dendritic cells (DCs) as antigen-presenting cells for T cell priming. DCs functional plasticity allows shaping the outcome of immune responses to achieve the required type of immunity. Therefore, the choice of adjuvants to guide and sustain DCs maturation, the design of multifaceted vehicles, and the choice of surface molecules to specifically target DCs represent the key issues currently explored in both preclinical and clinical settings. Here, we review advances in DCs-based vaccination approaches, which exploit direct <italic toggle="yes">in vivo</italic> DCs targeting and activation options. We also discuss the recent findings for efficient antitumor DCs-based vaccinations and combination strategies to reduce the immune tolerance promoted by the tumor microenvironment.</p></abstract><kwd-group><kwd>dendritic cells</kwd><kwd>vaccination</kwd><kwd>pattern recognition receptors</kwd><kwd>antigen delivery</kwd><kwd>adjuvants</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="180"/><page-count count="14"/><word-count count="13066"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Vaccines represent one of the most effective Copernican revolutions for humankind and world health. This innovative discovery by Edward Jenner in the late years of the XVIII century allowed for control or complete eradication of infectious diseases as smallpox (1979) and rinderpest virus (2011) (<xref rid="B1" ref-type="bibr">1</xref>). This immunization strategy posed the bases for current remarkable therapeutic approaches against not only infections but also cancer. In evolutionary terms, pathogens have acquired the capability to circumvent the immune system with several evasion mechanisms, revised elsewhere (<xref rid="B2" ref-type="bibr">2</xref>), that prevent pathogen clearance and the establishment of immune memory. Vaccines represent the unique tool we have to impede pathogen spread; therefore, the urgent need for efficient vaccines is as relevant as before. <italic toggle="yes">Mycobacterium tuberculosis</italic>, which causes tuberculosis, is currently one of the most feared infectious agent due to its capability to evade the immune system, leading to death of more than one million of people per year. Unbelievably, the only licensed vaccine against <italic toggle="yes">Mycobacterium tuberculosis</italic> is bacillus Calmette-Gu&#233;rin (BCG) conceived about 100&#8201;years ago. Nonetheless, BCG has displayed some degree of inefficacy in humans, thus raising the need for new tailored vaccination strategies that are currently under investigation (<xref rid="B3" ref-type="bibr">3</xref>). Moreover, every year, new cases of human immunodeficiency virus (HIV) infections lead to the necessity of a vaccine to control and prevent the spread of the virus. Up to now, vaccines against HIV have not passed phase II clinical trials due to poor protection conferred, requiring revision of delivered antigens (ags) and strategy to improve T cell response (<xref rid="B4" ref-type="bibr">4</xref>). Moreover, the recent outbreaks of Ebola virus and Zika virus infections clearly demonstrate that still nowadays more than few infectious diseases need to be overwhelmed, as reported by the World Health Organization. On the other hand, vaccines represent also a therapeutic tool against cancer. One of the hallmarks of cancer is the capability of tumor cells to evade immune-mediated destruction (<xref rid="B5" ref-type="bibr">5</xref>) by promoting a tolerant milieu. Therefore, the immune system has to be pushed to respond specifically and robustly against tumors cells.</p><p>To address this purpose, it is becoming more and more evident that dendritic cells (DCs) stand out as a potent tool in our hands, being the mediators of cellular and humoral responses (<xref rid="B6" ref-type="bibr">6</xref>). DCs have been discovered in 1973 by R. Steinman and Z. Cohn that divided phagocytic cells (discovered by E. Metchnikoff in 1887) in macrophages and DCs on the basis of different effector functions: microbial scavenging activities for macrophages and antigen-presenting function for DCs (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Since then, DCs have emerged as the most potent antigen-presenting cells capable of shaping adaptive responses both during infections and cancer. Moreover, the broad spectrum of DCs activation makes them suitable for fine shifting of the type of response the context needs. Taking advantage of new adjuvants, innovative ags-delivery carriers and targeting strategies, it is now feasible to optimize the activation and ag presentation processes by the specific DCs subset that is the most effective in the initiation of the adaptive response needed in a given context. Here, we discuss the diverse phenotypical and functional properties of DCs subtypes that are exploited by recently developed vaccine approaches, dealing with advances in the use of ags, adjuvants, carriers and DCs-expressed molecules, object of targeting.</p></sec><sec id="S2"><title>DCs Identity: A Multifaceted Functional Family</title><p>Dendritic cells are the primary professional antigen-presenting cells (APCs) that reside in both lymphoid and non-lymphoid organs (<xref rid="B9" ref-type="bibr">9</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>). DCs encompass several heterogeneous subsets whose subdivision relies on ontogeny, expression of surface-receptors, and transcription factors (<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). Much effort has been done in the identification and characterization of tissue-specific DC subsets to unravel the correlation between phenotype, localization, and functional properties, both in health and disease. Initially, DCs have been classified into conventional DCs (cDCs) and plasmacytoid DCs (pDCs). Briefly, cDCs prime na&#239;ve T cells and orchestrate ag-specific adaptive responses, while pDCs intervene during viral infections producing type I interferons (IFNs). Advanced approaches have extremely pushed our understanding of DC biology, resulting in a recent readapted taxonomy (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Indeed, Villani and colleagues identify six subsets of DCs and monocytes in human (Figure <xref ref-type="fig" rid="F1">1</xref>): DC1 (CLEC9A<sup>+</sup>CD141<sup>+</sup> DCs), DC2 and DC3 (CD1c<sup>+</sup> DCs), DC4 (FCGR3A/CD16<sup>+</sup> DCs), DC5 (AXL<sup>+</sup>SIGLEC6<sup>+</sup> DCs) and DC6 (pDCs). DC1 represent the cross-presenting CD141<sup>+</sup>/BDCA3<sup>+</sup> DCs while D2 and D3 correspond to cDCs displaying antigen uptake and processing capabilities. DC4 seem to be more prone to respond to viruses and are phenotypically close to monocytes. DC5 represent a newly defined subset that share features with both pDCs and cDCs, even though they appear to be functionally different from pDCs and more similar to cDCs. Indeed, DC5 localize in T cell zone of tonsils, probably promoting fast adaptive immunity. Due to this fine clustering, DC6 correspond to a more pure pDCs population (<xref rid="B12" ref-type="bibr">12</xref>). This precise classification opens the way for a more accurate view of DCs role in pathologies and provides cues for more specific targeting in immunotherapies. Indeed, it is reasonable to assume that this extreme phenotypical diversity correlates with different intrinsic functional properties of DCs, as emerged in Villani&#8217;s work (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). In addition, environmental cues dictate DC activation and drive specific T cell responses (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Indeed, DCs display a plethora of pattern recognition receptors (PRR) that are specifically bound by microbe- or damage-associated molecular pattern (PAMP and DAMP, respectively) (<xref rid="B21" ref-type="bibr">21</xref>). Upon receptors engagement in peripheral tissues, the transduction signals lead to DC maturation with the upregulation of co-stimulatory molecules (referred to as &#8220;signal 2&#8221;) and the pivotal chemokine receptor CCR7 that allows DCs migration through afferent lymphatic vessels to the draining lymph node (LN) (<xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>). In parallel, DCs mediate ag proteolysis to present intracellular peptides on major histocompatibility complex (MHC) class I to CD8<sup>+</sup> T cells and exogenous peptides on MHC II to CD4<sup>+</sup> T cells (referred as &#8220;signal 1&#8221;). DCs can present exogenous ags on MHC class I through the so-called cross-presentation, allowing them to induce CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) against viruses and tumor cells. Indeed, once in the LN, mature DCs encounter cognate na&#239;ve T cells and initiate adaptive responses (<xref rid="B25" ref-type="bibr">25</xref>). In the absence of maturation, as in steady-state conditions, the ag presentation and consequent migration to LN promote peripheral tolerance <italic toggle="yes">via</italic> T cell anergy or regulatory T cell formation (<xref rid="B26" ref-type="bibr">26</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>). Depending on the receptors engaged, DCs display different maturation states and produce different inflammatory mediators (often referred to as &#8220;signal 3&#8221;) that impact on the following cellular and humoral responses. The three signals released by DCs drive T helper (Th) cell differentiation. Briefly, DCs educate CD4<sup>+</sup> T cells against intracellular bacteria by promoting their polarization into IFN-&#947;-producing Th type 1 (Th1) cells. Upon infection by multicellular parasites, DCs, with the help of basophils, polarize CD4<sup>+</sup> T cells into Th type 2 (Th2) cells that produce mainly IL-4. For specialized mucosal and skin immunity, DCs drive the activation of Th type 17 (Th17) (<xref rid="B29" ref-type="bibr">29</xref>). Thus, polarization of T cells is a crucial event that provides mechanisms specifically orchestrated to restore physiological homeostasis. DCs undergo apoptosis once they have fulfilled their functions. The rapid DC turnover after activation is necessary to avoid excessive T cell activation (<xref rid="B30" ref-type="bibr">30</xref>) and to maintain self-tolerance (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). T lymphocyte activation culminates with the establishment of the immunological memory, providing the host with T cells more prone and efficient in responding to a reinfection by the same pathogen or upon tumor relapses (<xref rid="B33" ref-type="bibr">33</xref>). Besides, DCs are key players in humoral responses too. Indeed, they directly interact with B cells and indirectly support them by activating CD4<sup>+</sup> T cells, leading to humoral memory. All these notions strengthen the idea that DCs represent an optimal target for immunotherapies and vaccines, acting at the interface of innate and adaptive immunity.</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Dendritic cells (DCs) readapted taxonomy. Newly identified populations of blood human DCs are shown. DC1 subset is clearly distinct by the expression of CLEC9A, and it is specialized in cross-presentation of ags. DC2 and DC3 constitute the conventional DCs pool, even though they appear to be phenotypically slightly different and, upon stimulation with TLR ligands, their diversity emerges. DC4 is a population characterized by an upregulated Type I Interferon pathway for antiviral responses. DC5 has emerged as a new population whose specific functions are still unexplored. DC6 corresponds to the classic plasmacytoid DCs. These advances in the fine characterization of DCs in humans may shed light on the best subset to be targeted to incentivize the desired immune response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-09-01484-g001.jpg"/></fig></sec><sec id="S3"><title>Adjuvants Shaping DC Functions</title><p>To harness robust responses through DC-targeting vaccinations, DC maturation is essential. Adjuvants become compulsory complement of inactivated or subunit vaccines that may promote suboptimal responses. Furthermore, they improve DC migration, ag availability, and specific targeting. Although it seems clear that immunization could benefit from adjuvant uses, the solely adjuvant licensed in clinics, until recently, was alum (<xref rid="B34" ref-type="bibr">34</xref>). Despite alum has been used in vaccination practice since the beginning of the last century, the mechanism through which it activates innate immunity for the subsequent activation of adaptive immune responses remains elusive. The adjuvant properties of alum were initially attributed to the activation of NLRP3 inflammasome (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>); nevertheless, further studies have clearly shown the dispensability of NLRP3 and caspase-1 for the generation of responses in the presence of this adjuvant (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). TLR signaling is also dispensable for alum adjuvanticity (<xref rid="B39" ref-type="bibr">39</xref>) as well as mast cells, eosinophils, or macrophages (<xref rid="B40" ref-type="bibr">40</xref>). Recently, it has been proposed that upon contact with alum, DCs produce IL-2 through the activation of src and Syk kinases, Ca<sup>2+</sup> mobilization, and NFAT nuclear translocation. IL-2, in turn, is required for optimal T cell priming, activation, and antibody production (<xref rid="B41" ref-type="bibr">41</xref>). In addition to alum, other chemical adjuvants have been tested in preclinical models, showing a clear heterogeneity in the responses driven by different adjuvants, independently of the ag (<xref rid="B42" ref-type="bibr">42</xref>). This underlies the need of deepening our knowledge on these powerful tools to drive immune responses. Indeed, MF59, an oil-in-water emulsion adjuvant, that allows long-lasting ag retention in draining LN and enhanced ag uptake by LN-resident DCs, promotes robust humoral responses <italic toggle="yes">via</italic> follicular DC activation (<xref rid="B43" ref-type="bibr">43</xref>) and CD4<sup>+</sup> T cell immunity induction (<xref rid="B44" ref-type="bibr">44</xref>). Conversely, IC31 adjuvant, which consists of an antibacterial peptide and a synthetic oligodeoxynucleotide (ODN), elicits IFN-&#946; release by human DCs <italic toggle="yes">via</italic> engagement of endosomal TLRs supporting immunity against intracellular pathogens and cancer (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>In the last decades, attention has been focused on TLR ligands as adjuvants. Currently, several compounds are under investigation: Pam2CSK4, Pam3CSK4, or analogs as TLR2/6 or TLR2/1 ligands (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>), Poly(I:C) and similar compounds acting on TLR3 (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>), TLR4 agonists (<xref rid="B50" ref-type="bibr">50</xref>), Flagellin acting on TLR5 (<xref rid="B51" ref-type="bibr">51</xref>), Imiquimod and other TLR7 ligands (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>), TLR8 agonists (<xref rid="B54" ref-type="bibr">54</xref>), CpG ODN binding TLR9 (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). Due to the possible reactogenicity that may be induced by administering TLR agonists, some compounds are chemically modified to reduce toxicity or are delivered specifically to the DC subsets of interest, avoiding TLR ligand dissemination. Monophosphoryl lipid A, a low-toxicity molecule derived from lipopolysaccharide (LPS), displays promising effects for vaccine design (<xref rid="B57" ref-type="bibr">57</xref>) even though it promotes terminal differentiation of CD8<sup>+</sup> cells, leading to reduced memory protection (<xref rid="B58" ref-type="bibr">58</xref>). Another LPS-analog is 7-acyl lipid A that has emerged as potent inducer of IFN-&#947;-mediated ag-specific responses when co-delivered with poorly immunogenic tumor ags (<xref rid="B59" ref-type="bibr">59</xref>).</p><p>To improve the effectiveness and strength of immunity, in addition to the efficiency of APC, activation and ag processing and presentation of other aspects should be taken into account. The importance of DC-derived IL-2 in the activation of adaptive responses has been shown not only in alum-driven immune responses and in mouse models of infections (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>) but also in tests of human T cell priming in the presence of activatory DCs. During the first few hours after interaction with T cells, activatory monocyte-derived DCs (MoDCs stimulated with the cytokine cocktail, TNF-&#945;, IL-6, IL-1&#946;, and PGE<sub>2</sub>) produce IL-2 and CD25 (<xref rid="B62" ref-type="bibr">62</xref>). DC-derived IL-2 is, in turn, trans-presented to T cells at the immunological synapse <italic toggle="yes">via</italic> CD25. Since na&#239;ve T cells start to express CD25 only many hours after ag encounter, the DC-mediated presentation of the IL-2/CD25 complex is indispensable for an efficient T cell priming (<xref rid="B62" ref-type="bibr">62</xref>). It has been proposed that this is the reason why approved therapies based on the use of anti-CD25 antibodies to avoid the acute phases of autoimmune diseases, or acute rejection of kidney, heart, and hand transplants, are so efficient in interfering with T cell priming or T cell reactivation (<xref rid="B62" ref-type="bibr">62</xref>). Since IL-2 is produced in NFAT-dependent manner to improve the adjuvanticity of PRR agonists for vaccination purposes, the capacity of selected PRR agonists to induce NFAT signaling pathway activation and IL-2 production should be considered. Many PRR ligands have been shown to activate the NFAT transcription factor family members in innate immune cells (<xref rid="B63" ref-type="bibr">63</xref>). The NFAT pathway is activated in neutrophils, macrophages, and DCs in response to curdlan (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>), it is also activated in DCs in response to LPS (<xref rid="B30" ref-type="bibr">30</xref>) downstream of CD14, it is activated in response to mannose-capped lipoarabinomannan (Man-LAM), a major lipoglican of <italic toggle="yes">Mycobacterium tuberculosis</italic> (<xref rid="B66" ref-type="bibr">66</xref>), and downstream of TLR9 in response to &#946;-glucan bearing fungi (<xref rid="B67" ref-type="bibr">67</xref>). The production of IL-2 by innate immune cells during inflammatory responses is relevant not only for an efficient T cell priming but also for the skewing of T cell activation toward type I responses. In mice, DC-derived IL-2 is one of the cytokines required to elicit IFN-&#947; production from NK cells both in LPS-mediated inflammatory conditions and during fungal infections (<xref rid="B68" ref-type="bibr">68</xref>&#8211;<xref rid="B70" ref-type="bibr">70</xref>). IFN-&#947; potently activates macrophages and favors Th1 commitment of CD4<sup>+</sup> T cells. Therefore, early IFN-&#947; release by NK cells is not only crucial for controlling a variety of primary bacterial and fungal infections but also for the induction of type I immunity and memory, fundamental for the protection against bacterial, fungal, and viral infections and in antitumor immune therapies.</p><p>Another important reason for considering the capacity to activate the NFAT pathway in adjuvant selection tests is represented by the fact that NFATs regulate also the production of the prostanoid PGE<sub>2</sub> by activated DCs (<xref rid="B71" ref-type="bibr">71</xref>). PGE<sub>2</sub> promotes activated DC migration (<xref rid="B72" ref-type="bibr">72</xref>) and sustains vasodilation and local edema formation during the inflammatory process. This is particularly relevant for vaccination purposes since the increase of the interstitial pressure generated by the edema forces the fluids into the afferent lymphatics and favors a first wave of antigen arrival to the draining LN (<xref rid="B71" ref-type="bibr">71</xref>). Intriguingly, LN drainage of proteins or antigens occurs very rapidly after subcutaneous, intradermal, and intramuscular immunization (<xref rid="B73" ref-type="bibr">73</xref>&#8211;<xref rid="B75" ref-type="bibr">75</xref>), thus permitting an extremely fast uptake by phagocytes strategically localized in close proximity to the subcapsular sinus or lymphatic sinus of draining LN (<xref rid="B76" ref-type="bibr">76</xref>&#8211;<xref rid="B79" ref-type="bibr">79</xref>).</p><p>Antigen-presenting cells in LN then maintain the homeostasis of LN themselves and activate adaptive immune responses. In the last decades, the long-held paradigm of migratory DCs, resident in peripheral tissues as the skin, as unique APCs involved in T cell immunity has dramatically changed. Indeed, CD169<sup>+</sup> subcapsular sinus macrophages, medullary macrophages, and LN-resident DCs are LN sentinels that avoid excessive pathogen dissemination (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>) and mediators of immune responses (<xref rid="B76" ref-type="bibr">76</xref>).</p><p>Concerning migratory DCs and considering the skin, which represents the site of utmost importance for vaccination strategies due to the ease accessibility and the extremely high presence of DCs, skin-resident DCs have been subdivided into epidermal-resident Langerhans cells (LCs), which are Langerin<sup>+</sup> and two diverse subsets of dermal (d)DCs: Langerin<sup>+</sup> CD103<sup>+</sup> and Langerin<sup>&#8722;</sup> CD103<sup>&#8722;</sup> (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B82" ref-type="bibr">82</xref>). Upon infection, dDCs migrate to the LN within 10&#8211;24&#8201;h while LCs within 48&#8211;72&#8201;h, supporting long-lasting ag-presentation. Several works reveal the intrinsic differences between the two subsets in inducing Th or CTL responses, due to the particular cross-presenting capabilities of CD103<sup>+</sup> dDCs, for instance (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Once in the LN, whose strategical architecture enhances the probability of encounter between migratory DCs and cognate na&#239;ve T cell, adaptive immunity is initiated. Of note, LN-resident DCs are sufficient to promote early adaptive responses independently of migratory DCs when pathogens or antigens directly access the lymphatic conduits (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>). In antiviral responses, CD8&#945;<sup>+</sup> LN-resident DCs play a crucial role, thanks to their intrinsic capability of cross-presentation to CD8<sup>+</sup> CTL (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>) that may be supported by pDCs (<xref rid="B88" ref-type="bibr">88</xref>). In Herpes Simplex Virus (HSV) skin infection, CD8&#945;<sup>+</sup> LN-resident DCs uptake cargo-antigens, ferried by skin-resident migratory DCs in order to elicit CTL (<xref rid="B89" ref-type="bibr">89</xref>). Indeed, LCs and dDCs synergize with CD8&#945;<sup>+</sup> LN-resident DCs, which stand out as the most potent CTL inducers, preferentially sustaining CD4<sup>+</sup> Th responses both in influenza (<xref rid="B90" ref-type="bibr">90</xref>) and HSV cutaneous infections (<xref rid="B91" ref-type="bibr">91</xref>). In addition to CD8&#945;<sup>+</sup> LN-resident DCs, CD103<sup>+</sup> dDCs display intrinsic capability of cross-presentation, as their human counterpart, CLEC9A<sup>+</sup> CD141<sup>+</sup> DCs (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B96" ref-type="bibr">96</xref>). Besides, some authors demonstrated that blocking DC migration from the skin hinders CD4<sup>+</sup> T cell activation in response to subcutaneous bacterial (<xref rid="B97" ref-type="bibr">97</xref>) or soluble antigen challenge (<xref rid="B98" ref-type="bibr">98</xref>). Ablating Langerin<sup>+</sup> dDCs reduced T cell immunity strength, corroborating the notion that migratory DC complement LN-resident DC effects on adaptive responses (<xref rid="B99" ref-type="bibr">99</xref>&#8211;<xref rid="B101" ref-type="bibr">101</xref>). Nonetheless, the roles of LCs in activating T cells are still uncertain, probably due to the controversial functional properties of this innate subset (<xref rid="B102" ref-type="bibr">102</xref>&#8211;<xref rid="B104" ref-type="bibr">104</xref>). Despite this, the synergic effects of LN resident and migratory DCs seem to be undoubted (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B105" ref-type="bibr">105</xref>). Indeed, Allenspach and colleagues reported that ag presentation by LN-resident DCs few hours after the infection is required to entrap ag-specific T cells in the draining LN and to favor an optimal activation of T cells by migratory DCs that arrive at the LN many hours later (<xref rid="B106" ref-type="bibr">106</xref>).</p><p>It emerges, therefore, that another aspect to be considered for the identification of efficacious adjuvants concerns the type of DC subset to be targeted and the consequential effects that adjuvants imprint on that subset. Adjuvants play a pivotal role in determining tissue-resident DC mobility to draining LN and efficiency of T cell polarization. Indeed, dDCs acquire mobility after subcutaneous injection of Th1-specific adjuvants as CpG and LPS, but not with Th2-specific ones, as papain, or following contact sensitization with dibutyl phthalate and acetone. Moreover, dDCs are sufficient to promote Th1 and Th2 responses, while LCs are only supportive of Th1 (<xref rid="B107" ref-type="bibr">107</xref>). This evidence underscore that, in addition to the polarizing capabilities of adjuvants, also the targeted DC subset must be considered to elicit specific adaptive immunity. Indeed, Antonialli and colleagues reported differential immune responses when CD8&#945;<sup>+</sup> and CD8&#945;<sup>&#8722;</sup> DCs were targeted with the same ag and adjuvant, either CpG ODN or Flagellin (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>In addition, to enhance the efficacy of vaccination, the coincident delivery of ag and PRR adjuvants to APCs plays a crucial role. Encouraging evidence highlights the importance of conjugation of ag with PRR adjuvants, since it improves ag uptake, humoral and cellular responses when compared to vaccination with ag co-delivered with free TLR ligands (<xref rid="B109" ref-type="bibr">109</xref>). These findings strengthen the notion that adjuvants are formidable chiefs in shaping immune responses and must be selected for the outcomes they promote, in chemical association to the ag of interest.</p></sec><sec id="S4"><title>Novel Strategies of Vaccination: Multitasking Carriers</title><p>The traditional vaccination approaches consisted in the administration of live or attenuated micro-organisms. Up to now, several innovative strategies have emerged to address the need for efficient vaccines, especially against diseases that are critical to treat, as cancer and the infectious diseases already mentioned. The main purpose is to convey ag, adjuvant, and targeting-molecule in a unique compound to increase the efficacy of the ag-specific immune response. To address this issue, different approaches have been explored or are currently under investigation, as shown in Figure <xref ref-type="fig" rid="F2">2</xref>.</p><fig id="F2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Strategies of dendritic cells (DCs) targeting. Diverse approaches to deliver antigens to DCs are shown. <bold>(A)</bold> Recombinant antibody or single-chain variable fragment (scFv) specific for DC receptors are chemically conjugated with antigen and adjuvant molecules. scFv reduced dimension confers them higher tissue-penetrating properties. <bold>(B)</bold> Viral vector-based vaccines or naked DNA exploit the encoding machinery of DCs to translate antigens, adjuvants but also co-stimulatory molecules (&#8220;signal 2&#8221;) and cytokines (&#8220;signal 3&#8221;) increasing the activatory profile of DCs. Naked DNA could be delivered conjugated to nanoparticles (NPs) and liposomes. <bold>(C)</bold> Polymer-based NPs display physical and chemical properties that allow encapsulation or conjugation of antigens and adjuvants as well as ligands for specific DC receptors. Different polymer compositions provide diverse properties and dimension, allowing easy diffusion and/or retention in lymph node. <bold>(D)</bold> Liposomes allow both the encapsulation and intercalation in the phospholipid bilayer of antigens and adjuvants, depending on their chemical properties, as well as the functionalization of the surface with ligands of DC receptors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-09-01484-g002.jpg"/></fig><p>Recombinant antibody (rAb) represents a feasible option. This approach exploits the possibility to chemically fuse peptide ag, adjuvant, and targeting-molecule to Ab to tailor DCs targeting (<xref rid="B110" ref-type="bibr">110</xref>&#8211;<xref rid="B112" ref-type="bibr">112</xref>). In addition to rAb, single-chain fragments variable (scFv) revealed to be an appealing strategy due to their reduced size and enhanced infiltration into tissues, as in solid tumors (<xref rid="B113" ref-type="bibr">113</xref>).</p><p>Other approaches involve the use of nano-carries as vehicles. The most promising solution to target phagocytes is indeed the use of particulate materials (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). Nanoparticles (NPs) are the best candidates as delivery system, since they can be manipulated to efficiently and predominantly target phagocytes. This is possible, thanks to the versatility of NPs due to: (i) the large amounts of existing different nanomaterials; (ii) the possibility to adjust their size, morphology, and deformability with great precision; (iii) the possibility to load virtually any different type of drug molecules (<xref rid="B116" ref-type="bibr">116</xref>).</p><p>Viral vectors-based vaccines or virus-like particles rely on the intrinsic capability of viruses to infect cells and exploit their protein-encoding machinery, allowing expression in the cytosol of the engineered plasmid-genes, as ag, costimulatory molecules, cytokines, and adjuvants, providing the bases for strong CTL induction (<xref rid="B117" ref-type="bibr">117</xref>). On the other hand, naked DNA can be directly injected or conjugated to nano-carriers to favor specific targeting. The easy designing of nano-carriers-based vaccines along with their multi-component loading feature improve targeting of specific subsets (<xref rid="B118" ref-type="bibr">118</xref>) and shape immune responses (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>), favoring their application in several fields. In a cancer setting, nano-carriers allow to avoid killing of healthy cells, by delivering tumor ags or DNA encoding these peptides to APCs, inducing specific antitumor responses. Indeed, NPs allow endocytosis and MHC presentation on both class I and II (<xref rid="B121" ref-type="bibr">121</xref>) eliciting broad adaptive immunity, even against cancer cells. Rosalia and colleagues designed a polymer-based biodegradable poly(lactic-co-glycolic acid) PLGA NPs loaded with ag, Pam3CSK4, and Poly(I:C) and coated with an agonistic &#945;CD40-monoclonal Ab (NP-CD40). This multi-functional strategy resulted in efficient and selective delivery of NPs to DCs <italic toggle="yes">in vivo</italic> upon s.c. injection and induced priming of CD8<sup>+</sup> T cells against tumor associated ags, increasing tumor-bearing mice survival (<xref rid="B109" ref-type="bibr">109</xref>). PLGA NPs carrying the poorly immunogenic melanoma-derived antigen tyrosinase-related protein 2 along with 7-acyl lipid A, manage in breaking the immunotolerance acting against tumor-antigens. Indeed, administration of the abovementioned NPs resulted in antigen-specific CD8<sup>+</sup> CTL responses, characterized by IFN-&#947; production and increase of pro-inflammatory cytokines in the tumor microenvironment (TME) (<xref rid="B59" ref-type="bibr">59</xref>). Another nano-carrier-based approach relies on liposome, self-assembled vesicles composed by lipid bilayers with high functionalizing properties. Besides, Maji and colleagues reported that after uptake by DCs, cationic liposomes localize in endosomal compartments that allow ag presentation preferentially on MHC I but do not exclude MHC II ag presentation (<xref rid="B122" ref-type="bibr">122</xref>), suggesting a crucial role in antitumor or antiviral immunity supported by Th responses.</p><p>In addition to the use of NPs, targeting DC-specific receptors has become an attractive strategy for vaccine development due to the enforced efficiency of immune responses when compared to generic-delivering approaches. Here, we report the more characterized DCs receptors, currently under investigation in the scenario of tailored-vaccination, as shown in Table <xref rid="T1" ref-type="table">1</xref>.</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Targeted receptors for tailored ags delivery.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Receptor</th><th valign="top" align="left" rowspan="1" colspan="1">Expression</th><th valign="top" align="left" rowspan="1" colspan="1">Activity</th><th valign="top" align="left" rowspan="1" colspan="1">Clinical trials</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CLEC9A</td><td align="left" valign="top" rowspan="1" colspan="1">C-type lectin receptor</td><td align="left" valign="top" rowspan="1" colspan="1">Human: CD11c<sup>+</sup> CD141<sup>+</sup> XCR1<sup>+</sup> conventional DCs (cDCs)<break/>CD14<sup>+</sup> CD16<sup>-</sup> monocytes<break/>MOUSE: plasmacytoid DCs (pDCs)<break/>XCR1<sup>+</sup> CD8&#945;<sup>+</sup> lymph node-resident dendritic cells (DCs)</td><td align="left" valign="top" rowspan="1" colspan="1">Major histocompatibility complex (MHC) class I<break/>MHC class II<break/>Ag presentation</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DEC-205</td><td align="left" valign="top" rowspan="1" colspan="1">Endocytic receptor</td><td align="left" valign="top" rowspan="1" colspan="1">Human: cDCs, monocytes, B cells<break/>MOUSE: CD8&#945;<sup>+</sup> DCs<break/>Dermal/interstitial DCs<break/>Langerhans cells</td><td align="left" valign="top" rowspan="1" colspan="1">MHC class I<break/>MHC class II<break/>Ag presentation</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03358719">NCT03358719</ext-link>: recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01834248">NCT01834248</ext-link>: completed<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02166905">NCT02166905</ext-link>: recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01522820">NCT01522820</ext-link>: completed</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD40</td><td align="left" valign="top" rowspan="1" colspan="1">Transmembrane glycoprotein<break/>Surface receptor</td><td align="left" valign="top" rowspan="1" colspan="1">Human/mouse: cDCs and pDCs, monocytes, B cells, endothelial cells</td><td align="left" valign="top" rowspan="1" colspan="1">DCs activation</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03329950">NCT03329950</ext-link>: recruiting<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02706353">NCT02706353</ext-link>: recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03214250">NCT03214250</ext-link>: recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03389802">NCT03389802</ext-link>: recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03418480">NCT03418480</ext-link>: recruiting<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03123783">NCT03123783</ext-link>: recruiting</td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p><italic toggle="yes"><sup>a</sup>There are currently more than 30 clinical trials involving the anti-CD40 antibody. Here, the more recent trials regarding DCs-based vaccination strategies are reported</italic>.</p></fn></table-wrap-foot></table-wrap><p>CLEC9A or DNGR1 is a C-type lectin receptor that mediates endocytosis, but not phagocytosis, with low pH endosomes promoting the drift toward cross-presentation. Importantly, CLEC9A binding of antigens induces antigen presentation on both MHC I (cross-presentation) and MHC II. It is highly and specifically expressed on CD11c<sup>+</sup>CD141<sup>+</sup>XCR1<sup>+</sup> cDCs and CD14<sup>+</sup>CD16<sup>&#8722;</sup> monocytes in human and in murine pDCs and XCR1<sup>+</sup> CD8a<sup>+</sup> LN resident but not CD103<sup>+</sup>XCR1<sup>+</sup> migrating DCs (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>). Indeed, CD141<sup>+</sup>XCR1<sup>+</sup> DCs constitute the human counterpart of CD8&#945;<sup>+</sup> XCR1<sup>+</sup> murine DCs (<xref rid="B125" ref-type="bibr">125</xref>). They share XCR1, the receptor of XCL1. XCL1 is released by activated T cells and the axis XCR1&#8211;XCL1 is necessary for robust CTL responses (<xref rid="B126" ref-type="bibr">126</xref>). CD141<sup>+</sup>XCR1<sup>+</sup> DCs are the main cross-presenting DCs in human, thus they appear promising for CTL-mediated responses, in tumors and viral infections (<xref rid="B127" ref-type="bibr">127</xref>). This specific subset is characterized by the expression of TLR3 that may be exploited to fully activate CLEC9A<sup>+</sup>XCR1<sup>+</sup> DCs since antibody binding of CLEC9A leads to its rapid internalization but not TLR-pathway activation, preventing pro-inflammatory cytokine production and full maturation of DCs (<xref rid="B127" ref-type="bibr">127</xref>). Conversely, Caminschi and Li independently demonstrated the potentiality of targeting Clec9A that resulted in enhanced humoral immunity independently of TRIF-MyD88 or TLR4 pathway, even in the absence of adjuvants (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>). Targeting Clec9A induces enhanced CD4<sup>+</sup> T cell proliferation <italic toggle="yes">in vivo</italic>, which supports B cell immunity, when compared to the targeting of another endocytic receptor, discussed later, DEC-205, independently of the use of adjuvants as CpG (<xref rid="B130" ref-type="bibr">130</xref>). Some years later, different authors demonstrated that this strong humoral response is endorsed by the establishment of follicular T helper cells memory, even upon vaccination with glycoprotein D of HSV, both in mice and non-human primates (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>). These promising results were confirmed also in a human <italic toggle="yes">in vitro</italic> setting, on CD141<sup>+</sup> DCs (<xref rid="B133" ref-type="bibr">133</xref>). Finally, the efficacy of targeting Clec9A has been evaluated in the delivery of poorly immunogenic virus-derived antigens. Park and colleagues managed in conferring specific humoral response, protective upon reinfection (<xref rid="B134" ref-type="bibr">134</xref>). Thus, exploiting the specific expression of this receptor on the most specialized DCs in cross-presentation in combination with TLR3 ligands, will enhance antiviral and anticancer responses (<xref rid="B135" ref-type="bibr">135</xref>), combined with robust humoral immunity.</p><p>DEC-205 or CD205 is a 205&#8201;kDa endocytic receptor that has a cysteine-rich domain, a fibronectin type II domain, and 10 C-type lectin-like domains, as well as an internalization sequence in its cytoplasmic tail (<xref rid="B136" ref-type="bibr">136</xref>). Thus, it mediates cross-presentation through clathrin- and dynamin-dependent receptor-mediated endocytosis. Indeed, it is expressed by the most professional cross-presenting DCs, the CD8&#945;<sup>+</sup> DCs subtype, while CD8&#945;<sup>&#8722;</sup> DCs display very low level of this receptor. In addition, DEC-205 is found on dermal/interstitial DCs and LCs (<xref rid="B137" ref-type="bibr">137</xref>), thus guaranteeing ag delivery to both skin-resident and LN-resident professional APCs. In humans, DEC-205 is shared among cDCs, monocytes, and B cells, while pDCs, granulocytes, NK cells, and T lymphocytes express low levels of this receptor (<xref rid="B138" ref-type="bibr">138</xref>). In addition, DEC-205 regulates molecule recycling through late endosomes, promoting also MHC II presentation to CD4<sup>+</sup> T cells in LCs (<xref rid="B139" ref-type="bibr">139</xref>). Steinman and Nussenzweig have addressed this molecule to improve vaccine efficacy since 2000 (<xref rid="B140" ref-type="bibr">140</xref>). By taking advantage of anti-DEC-205 rAb conjugated to OVA peptide, they demonstrated that s.c. injections of this compound lead to a strong IFN-&#947; and IL-2-mediated immunity only when DCs activation was supported by &#945;CD40 mAb, otherwise, tolerance against the OVA peptide occurs (<xref rid="B141" ref-type="bibr">141</xref>). Indeed, diversely from PRR agonists, antibody crosslinking the DEC-205 does not induce DCs maturation (<xref rid="B142" ref-type="bibr">142</xref>). Furthermore, few years later, the combined strategy of anti-DEC-205 and &#945;CD40 was reported to confer protection against melanoma and intranasal influenza infection (<xref rid="B112" ref-type="bibr">112</xref>). In a viral setting, anti-DEC-205 rAb chemically coupled with HIV p24 gag protein tested <italic toggle="yes">in vitro</italic> on blood cells derived by 11 HIV-infected donors has revealed efficient expansion of IFN-&#947;-producing CD8<sup>+</sup> T lymphocytes (<xref rid="B143" ref-type="bibr">143</xref>) from all the different donors. This indicated that DCs and CD205 can lead to the generation of different peptides from a single protein. Moreover, vaccines based on the filamentous bacteriophage fd presenting an &#945;DEC-205 scFv, efficiently induce DCs maturation <italic toggle="yes">via</italic> the activation of the TLR9-MyD88 pathway (<xref rid="B144" ref-type="bibr">144</xref>), without adjuvants and further elicit potent antitumor responses when compared to non-tailored ag delivery (<xref rid="B145" ref-type="bibr">145</xref>). Intriguingly, DEC-205, orphan of a specific ligand, has been proven to be necessary for CpG uptake and eventual DC activation (<xref rid="B146" ref-type="bibr">146</xref>).</p><p>CD40 is a molecule belonging to the TNF receptor family, expressed by several cell types and among these, DCs. It has emerged as a receptor for the human chaperone Heat shock protein (Hsp) 70 that mediates the internalization of peptides bound to Hsp70 itself (<xref rid="B147" ref-type="bibr">147</xref>). Moreover, upon activation, T cell transiently expresses CD40L allowing cross-linking of CD40 on DCs and completing their maturation. From these notions, CD40 appeared an interesting molecule to target for DC-based vaccination strategies. Indeed, by engineering antibody chemical structure, Schjetne and colleagues demonstrated the efficacy of CD40 engagement conferring protection against myeloma- and lymphoma-derived ags (<xref rid="B148" ref-type="bibr">148</xref>). Moreover, through the co-administration of two DNA-based vaccines encoding either CD40 and the foot-and-mouth disease-derived ags, the transient increase of endogenous &#945;CD40 antibodies allows an efficacious DCs activation and an efficient development of ag-specific T cell immunity, if compared to the administration of DNA encoding ags alone (<xref rid="B149" ref-type="bibr">149</xref>). Further promising results have been obtained in a vaccine against cyclin-D1 that is overexpressed by mantle cell lymphoma (MCL). Thanks to algorithm analysis, Chen and colleagues identified three cyclin-D1-derived peptides that efficiently bind to MHC class I of DCs, potentially overexpressed in all MCL patients. By generating a rAb targeting CD40, they efficiently delivered these tumor associated ags to DCs and mounted IFN-&#947;-specific T cell responses in patients-derived peripheral blood mononuclear cells (<xref rid="B150" ref-type="bibr">150</xref>). Thus, CD40 represents a specific DC-targeting molecule that has been used in combination with other targeting approaches to support specific DCs activation, avoid tolerance, and induce robust T cell immunity (<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B141" ref-type="bibr">141</xref>).</p></sec><sec id="S5"><title>DCs and Cancer</title><p>When evaluating vaccination strategies for cancer patients, it is compulsory to take into account one of the hallmarks of cancer: avoiding immune destruction by promoting tolerance and disarming the immune system (<xref rid="B5" ref-type="bibr">5</xref>). The orchestration of antitumor responses involves multiple protagonists and mediators, among these, cytotoxic T cells and NK cells, whose activation is supported by DCs (<xref rid="B151" ref-type="bibr">151</xref>). Furthermore, DCs-based vaccines has emerged as more efficient in promoting T cell immunity if compared to peptide-based vaccination approaches (<xref rid="B152" ref-type="bibr">152</xref>). Thus, much effort has been made to improve strategies of DCs-based vaccination in neoplastic diseases, to ameliorate the prognosis or eradicate both primary tumor and metastases. Up to now, two different approaches have been addressed: <italic toggle="yes">ex vivo</italic> generation of autologous pulsed DCs and direct <italic toggle="yes">in vivo</italic> targeting of DCs, as previously discussed. The former strategy provides a better control of the maturation and activation state of DCs and a specific load of the ag to the selected DCs subset. Despite this, intense work is needed to generate this vaccine, since it is personalized for each patient and only few subsets of DCs are feasibly generated <italic toggle="yes">in vitro</italic> or collected <italic toggle="yes">ex vivo</italic>, limiting the access of ags to other more functionally driven subsets. Diversely, the <italic toggle="yes">in vivo</italic> targeting methods allow the generation of large amount of vaccine in a one-step procedure, and the targeting of diverse DCs subsets in their natural environment.</p><p>Once the DCs-based vaccine is generated, the efficacy of antitumoral responses has to be evaluated. It is mainly related to (i) the capability to establish specific antitumor-associated ag (TAA) immunity and (ii) the overcome of the tolerogenic status promoted by the TME.</p><p>To select highly immunogenic ags, multiple solutions have been tested: whole tumor lysate or killed tumor cells, synthetic long peptides (SLPs), full length proteins, transfection or electroporation with DNA or mRNA coding for TAA, transduction with lentiviral vectors and neoantigens. The availability of an elevated number of antigens through the incubation of DCs with whole tumor lysates or autologous tumor cells allows the presentation of multiple epitopes, loaded on both MHC class I or II, which leads to Th and cytotoxic responses. Indeed, several clinical trials are currently evaluating the benefits obtained by using this approach (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01875653">NCT01875653</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00045968">NCT00045968</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02496520">NCT02496520</ext-link>). SLPs are 28&#8211;35 aa long peptides cross-presented by DCs (<xref rid="B153" ref-type="bibr">153</xref>), currently under investigation in both preclinical and clinical setting. Compared to short synthetic peptides, the use of SLPs lacks the necessity to know the patients&#8217; HLA haplotype, thus permitting their full exploitation in a larger cohort of people. Moreover, SLPs administration to DCs leads to an enhanced CD8<sup>+</sup> T cells activation since, once engulfed, they rapidly escape from the endolysosome to follow the path of MHC class I presentation, fundamental in antitumor responses. Indeed, SLPs and DCs-based vaccines are showing promising results in terms of safety and immunogenicity, in both preclinical and clinical settings (<xref rid="B154" ref-type="bibr">154</xref>). They have gained attention in the context of human papilloma virus cervical (<xref rid="B155" ref-type="bibr">155</xref>), ovarian (<xref rid="B156" ref-type="bibr">156</xref>), and colorectal cancer (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>), displaying immunogenic capacities, in terms of antibody production and CD4<sup>+</sup> and CD8<sup>+</sup> T cell activation, when delivered with adjuvants, as poly ICLC, Montanide-ISA-51 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02334735">NCT02334735</ext-link>), and IFN&#945;. When comparing SLPs and full length proteins, it has emerged that DCs process SLPs better that full length protein, due to the slower processing route the latter display (<xref rid="B154" ref-type="bibr">154</xref>). Concerning transfection or electroporation of DCs with mRNA or DNA encoding, not only for TAA but also for costimulatory molecules and cytokines, to enforce adaptive immunity, has proven to be efficacious in inducing antitumor CD4<sup>+</sup> and CD8<sup>+</sup> T cells expansion, mediated by DCs targeting (<xref rid="B159" ref-type="bibr">159</xref>). A similar approach regards <italic toggle="yes">in vivo</italic> lentiviral transduction of DCs, which displays versatility for gene delivery and efficient transduction for non-dividing cells, as DCs. Indeed, Bryson et al. conceived a multifunctional vaccine composed by a modified lentivirus, whose glycoproteins can directly target DC-SIGN on DCs, loaded with breast cancer ags, alpha lactalbumin, and erb-b2 receptor tyrosine kinase 2. Single injections of the compound provided tumor self-ags-specific CD8<sup>+</sup> T cell immunity, reducing tumor growth (<xref rid="B160" ref-type="bibr">160</xref>). Despite the improvements derived by these advanced strategies, in the last years, neoantigens are becoming more and more appealing (<xref rid="B161" ref-type="bibr">161</xref>). During tumor progression, cancer cells give rise to neoantigens, novel ags different from the self-tumor ags, derived by the tumor-specific mutations. Therefore, prediction tools, RNA mutanome, and deep-sequencing have allowed the identification of specific non-self-ags that are fundamental in strong T cell immunity (<xref rid="B162" ref-type="bibr">162</xref>&#8211;<xref rid="B164" ref-type="bibr">164</xref>). Indeed, several clinical trials are currently investigating the potential of neoantigens (NCT0235956; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01970358">NCT01970358</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02149225">NCT02149225</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02348320">NCT02348320</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02316457">NCT02316457</ext-link>). As emerged, different strategies of ags selection have been explored and, even though one strategy may result in a more enforced antitumor immunity if compared to another, still the issue of the TME negative influence on the immune system has to be faced. Indeed, the TME actively suppresses the activation of the immune system. Tumor cells secrete immunosuppressive cytokines, as vascular endothelial growth factor (<xref rid="B165" ref-type="bibr">165</xref>, <xref rid="B166" ref-type="bibr">166</xref>), macrophage colony-stimulating factor (<xref rid="B167" ref-type="bibr">167</xref>), transforming growth factor &#946; (TGF-&#946;) (<xref rid="B168" ref-type="bibr">168</xref>), and IL-10 (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>). Even though some of these cytokine display controversial roles, depending on the pathological context, they generally promote DCs tolerogenicity, by limiting their activation and increasing their expression of pro-tumor molecules, such as programmed cell death 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO). Therefore, tolerogenic DCs lead to T cells anergy, Tregs expansion, and Th1 responses inhibition. Phenotypical characterization of immune cells isolated from breast cancer patients, highlighted the functional alteration in DCs, T, and NK cells in promoting antitumor responses (<xref rid="B171" ref-type="bibr">171</xref>). Furthermore, tumor cells retain DCs into the TME, preventing their migration to draining LNs and promoting metastatization (<xref rid="B172" ref-type="bibr">172</xref>). To address this issue, some <italic toggle="yes">ex vivo</italic> generated DCs-based vaccines are directly administered intranodally, as for the CD1c<sup>+</sup> DCs pulsed with HLA-A2.1-restricted tumor peptides administered to patients with stage IV melanoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01690377">NCT01690377</ext-link>), which generated tumor-specific CD8<sup>+</sup> T cells responses and further improvement of survival (<xref rid="B173" ref-type="bibr">173</xref>). To reduce the tolerogenic influence of the TME on DCs, the positive role of GM-CSF in improving DCs survival and responsiveness is currently exploited in some clinical trials like a phase I/II trial with a DC/tumor cell fusion vaccine administered in association with GM-CSF to treat renal cancer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00458536">NCT00458536</ext-link>). Similarly, others are focusing their attention on FMS-like tyrosine kinase 3-ligand (FLT3L), another crucial DCs growth factor, in combination with other compounds (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01811992">NCT01811992</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01976585">NCT01976585</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02129075">NCT02129075</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02839265">NCT02839265</ext-link>). FLT3L has, indeed, been shown to increase the efficacy of proteins- and RNA-based vaccines, due to a maturation effect on DCs (<xref rid="B174" ref-type="bibr">174</xref>&#8211;<xref rid="B176" ref-type="bibr">176</xref>). Additional efforts made to counteract the tolerogenic influence of the TME include the use of PD-1 and IDO inhibitors. Co-administration of anti-PD-1 molecules increases the efficacy of DCs-based vaccines, in terms of enforced intratumoral CD8<sup>+</sup> T cell responses and trafficking of CD8<sup>+</sup> memory T cells, as observed in a preclinical model of glioblastoma (<xref rid="B177" ref-type="bibr">177</xref>). In parallel, several clinical trials are aiming at evaluating the efficacy of DCs-based vaccines combined with anti-PD-1 agents (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03014804">NCT03014804</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03325101">NCT03325101</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03035331">NCT03035331</ext-link>). The other tolerogenic marker addressed in cancer immunotherapy and DCs-based vaccine is IDO. Indeed, silencing approaches to reduce the expression of IDO in DCs for vaccination in preclinical models, have resulted in decreased T cell apoptosis, reduced numbers of Tregs, decreased tumor size when compared to mice that had received ags-loaded DCs without IDO silencing (<xref rid="B178" ref-type="bibr">178</xref>). IDO inhibitors in DCs vaccination are currently being tested in phase II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01560923">NCT01560923</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01042535">NCT01042535</ext-link>).</p><p>All these approaches have explored different scenarios to evaluate the more efficient therapeutic combination that seems to move toward personalized vaccinations for cancer patients.</p></sec><sec id="S6"><title>Concluding Remarks</title><p>In this review, we have underscored the crucial role of DCs in orchestrating immune responses and; therefore, the great interest in targeting these cells in novel vaccination strategies. We have reported examples of different approaches aimed at amplifying the efficiency of immunizations against cancer or infectious diseases. Indeed, the urgent need of vaccines is as relevant as before because of newly emerging diseases with ineffective current therapies. Deepen the mechanisms underlying these pathologies may provide cues on the more appropriate design of vaccines and by merging diverse tailoring strategies we could enforce the immune system. As a matter of fact, it is suggested to act on different fronts when designing new vaccines, since several factors must be considered: (i) targeting DC subsets specialized in initiating the desired cellular or humoral immunity/memory; (ii) adjuvants that strengthen and drive T and B cell responses; (iii) fine and optimized selection of the immunogenic ags to drive enforced responses; (iv) novel strategies to convey ags and adjuvants to DCs; (v) route of administration. Starting from these notions, in the last decades, enormous efforts have been made to tailor vaccination strategies. New technologies as well as recent advances have allowed extreme flexibility in designing vaccines and shaping the following outcomes. Nowadays, researchers do have smart tools to manipulate immune responses with prophylactic or therapeutic vaccinations. The abovementioned findings pave the way for possible therapeutic approaches, theoretically applicable to all pathological contexts. Despite this encouraging evidence, several limitations or issues still have to be overcome. Indeed, more than a few vaccines do not pass phases I of clinical trials either for toxicity issues and lack of immunogenicity in some individuals. What is missing? Part of the answer to this question could sit on human genetics and population variability. Syngeneic animal models are ideal settings in which the systems are pushed although they constitute a necessary and useful step preceding clinical trials.</p><p>Moreover, when translating vaccine testing from <italic toggle="yes">in vivo</italic> experiments on animals to <italic toggle="yes">ex vivo</italic> on human cells, often the opted choice are blood human cells, while in most of the cases vaccines will be administered in the skin, having a complete different DCs-based milieu (<xref rid="B15" ref-type="bibr">15</xref>). Crucially, Idoyaga and colleagues dissected the interindividual variability in skin-resident DCs, stressing the need of shedding light on the effects that genetics and environment imprint on DCs. It is compulsory to decode the complex scenario of human diversity to provide personalized therapies with increased efficacy. In the Omics era, systems biology and computational modeling integrate huge data-sets to address the urgent need of information on the global behavior. Indeed, Genome-wide association studies have provided insights into human genetics variants associated to the immunogenicity of vaccines (<xref rid="B179" ref-type="bibr">179</xref>, <xref rid="B180" ref-type="bibr">180</xref>). Therefore, integration of &#8220;wet&#8221; evidence and &#8220;dry&#8221; notions may fasten the designing process and provide both efficient vaccine strategies and their predictive efficacy.</p></sec><sec id="S7"><title>Author Contributions</title><p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> IZ is supported by NIH grant 1R01AI121066-01A1, 1R01DK115217, CCFA Senior Research Awards (412708), the Eleanor and Miles Shore 50th Anniversary Fellowship Program, and the Cariplo Foundation (2014-0859). FG is supported by Associazione Italiana per la Ricerca sul Cancro (IG 2016Id.18842), Cariplo Foundation (Grant 2014-0655), and Fondazione Regionale per la Ricerca Biomedica (FRRB).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>CD</given-names></name></person-group><article-title>Eradicating infectious disease: can we and should we?</article-title><source>Front Immunol</source> (<year>2011</year>) <volume>2</volume>:<fpage>1</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2011.00053</pub-id><pub-id pub-id-type="pmid">22566843</pub-id><pub-id pub-id-type="pmcid">PMC3341977</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finlay</surname><given-names>BB</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>G</given-names></name></person-group>. <article-title>Anti-immunology: evasion of the host immune system by bacterial and viral pathogens</article-title>. <source>Cell</source> (<year>2006</year>) <volume>124</volume>(<issue>4</issue>):<fpage>767</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2006.01.034</pub-id><pub-id pub-id-type="pmid">16497587</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davenne</surname><given-names>T</given-names></name><name name-style="western"><surname>McShane</surname><given-names>H</given-names></name></person-group><article-title>Why don&#8217;t we have an effective tuberculosis vaccine yet?</article-title><source>Expert Rev Vaccines</source> (<year>2016</year>) <volume>15</volume>(<issue>8</issue>):<fpage>1009</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1586/14760584.2016.1170599</pub-id><pub-id pub-id-type="pmid">27010255</pub-id><pub-id pub-id-type="pmcid">PMC4950406</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahay</surname><given-names>B</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>CQ</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>JK</given-names></name></person-group>. <article-title>Conserved HIV epitopes for an effective HIV vaccine</article-title>. <source>J Clin Cell Immunol</source> (<year>2017</year>) <volume>8</volume>(<issue>4</issue>):<fpage>518</fpage>.<pub-id pub-id-type="doi">10.4172/2155-9899.1000518</pub-id><pub-id pub-id-type="pmid">29226015</pub-id><pub-id pub-id-type="pmcid">PMC5719888</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source> (<year>2011</year>) <volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name></person-group>. <article-title>Dendritic cells and the control of immunity</article-title>. <source>Nature</source> (<year>1998</year>) <volume>392</volume>:<fpage>245</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name><name name-style="western"><surname>Chon</surname><given-names>ZA</given-names></name></person-group>. <article-title>Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution</article-title>. <source>J Exp Med</source> (<year>1973</year>) <volume>137</volume>:<fpage>1142</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1084/jem.137.5.1142</pub-id><pub-id pub-id-type="pmid">4573839</pub-id><pub-id pub-id-type="pmcid">PMC2139237</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>ZA</given-names></name></person-group><article-title>Identification of a novel cell type in peripheral lympoid organs of mice. II. Functional properties in vitro</article-title>. <source>J Exp Med</source> (<year>1974</year>) <volume>139</volume>:<fpage>380</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1084/jem.139.2.380</pub-id><pub-id pub-id-type="pmid">4589990</pub-id><pub-id pub-id-type="pmcid">PMC2139525</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granot</surname><given-names>T</given-names></name><name name-style="western"><surname>Senda</surname><given-names>T</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>N</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>J</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Dendritic cells display subset and tissue-specific maturation dynamics over human life</article-title>. <source>Immunity</source> (<year>2017</year>) <volume>46</volume>(<issue>3</issue>):<fpage>504</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.019</pub-id><pub-id pub-id-type="pmid">28329707</pub-id><pub-id pub-id-type="pmcid">PMC5415308</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilliams</surname><given-names>M</given-names></name><name name-style="western"><surname>Dutertre</surname><given-names>CA</given-names></name><name name-style="western"><surname>Scott</surname><given-names>CL</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>N</given-names></name><name name-style="western"><surname>Sichien</surname><given-names>D</given-names></name><name name-style="western"><surname>Chakarov</surname><given-names>S</given-names></name><etal/></person-group><article-title>Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>(<issue>3</issue>):<fpage>669</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.015</pub-id><pub-id pub-id-type="pmid">27637149</pub-id><pub-id pub-id-type="pmcid">PMC5040826</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elpek</surname><given-names>KG</given-names></name><name name-style="western"><surname>Bellemare-Pelletier</surname><given-names>A</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>D</given-names></name><name name-style="western"><surname>Reynoso</surname><given-names>ED</given-names></name><name name-style="western"><surname>Lukacs-Kornek</surname><given-names>V</given-names></name><name name-style="western"><surname>DeKruyff</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>(<issue>8</issue>):<fpage>e23921</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0023921</pub-id><pub-id pub-id-type="pmid">21886840</pub-id><pub-id pub-id-type="pmcid">PMC3158776</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villani</surname><given-names>AC</given-names></name><name name-style="western"><surname>Satija</surname><given-names>R</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>G</given-names></name><name name-style="western"><surname>Sarkizova</surname><given-names>S</given-names></name><name name-style="western"><surname>Shekhar</surname><given-names>K</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors</article-title>. <source>Science</source> (<year>2017</year>) <volume>356</volume>(<issue>6335</issue>):<fpage>eaah4573</fpage>.<pub-id pub-id-type="doi">10.1126/science.aah4573</pub-id><pub-id pub-id-type="pmid">28428369</pub-id><pub-id pub-id-type="pmcid">PMC5775029</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidkamp</surname><given-names>GF</given-names></name><name name-style="western"><surname>Sander</surname><given-names>J</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>CHK</given-names></name><name name-style="western"><surname>Heger</surname><given-names>L</given-names></name><name name-style="western"><surname>Eissing</surname><given-names>N</given-names></name><name name-style="western"><surname>Baranska</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment</article-title>. <source>Sci Immunol</source> (<year>2016</year>) <volume>1</volume>(<issue>6</issue>):<fpage>eaai7677</fpage>.<pub-id pub-id-type="doi">10.1126/sciimmunol.aai7677</pub-id><pub-id pub-id-type="pmid">28783692</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merad</surname><given-names>M</given-names></name><name name-style="western"><surname>Sathe</surname><given-names>P</given-names></name><name name-style="western"><surname>Helft</surname><given-names>J</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name><name name-style="western"><surname>Mortha</surname><given-names>A</given-names></name></person-group>. <article-title>The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting</article-title>. <source>Annu Rev Immunol</source> (<year>2013</year>) <volume>31</volume>(<issue>1</issue>):<fpage>563</fpage>&#8211;<lpage>604</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-074950</pub-id><pub-id pub-id-type="pmid">23516985</pub-id><pub-id pub-id-type="pmcid">PMC3853342</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alc&#225;ntara-Hern&#225;ndez</surname><given-names>M</given-names></name><name name-style="western"><surname>Leylek</surname><given-names>R</given-names></name><name name-style="western"><surname>Wagar</surname><given-names>LE</given-names></name><name name-style="western"><surname>Engleman</surname><given-names>EG</given-names></name><name name-style="western"><surname>Keler</surname><given-names>T</given-names></name><name name-style="western"><surname>Marinkovich</surname><given-names>MP</given-names></name><etal/></person-group><article-title>High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization</article-title>. <source>Immunity</source> (<year>2017</year>) <volume>47</volume>(<issue>6</issue>):<fpage>1037</fpage>&#8211;<lpage>50.e6</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.001</pub-id><pub-id pub-id-type="pmid">29221729</pub-id><pub-id pub-id-type="pmcid">PMC5738280</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>See</surname><given-names>P</given-names></name><name name-style="western"><surname>Dutertre</surname><given-names>CA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>P</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>N</given-names></name><name name-style="western"><surname>Irac</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Mapping the human DC lineage through the integration of high-dimensional techniques</article-title>. <source>Science</source> (<year>2017</year>) <volume>356</volume>(<issue>6342</issue>):<fpage>eaag3009</fpage>.<pub-id pub-id-type="doi">10.1126/science.aag3009</pub-id><pub-id pub-id-type="pmid">28473638</pub-id><pub-id pub-id-type="pmcid">PMC7611082</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mildner</surname><given-names>A</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S</given-names></name></person-group>. <article-title>Development and function of dendritic cell subsets</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>40</volume>(<issue>5</issue>):<fpage>642</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.04.016</pub-id><pub-id pub-id-type="pmid">24837101</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segura</surname><given-names>E</given-names></name><name name-style="western"><surname>Valladeau-Guilemond</surname><given-names>J</given-names></name><name name-style="western"><surname>Donnadieu</surname><given-names>M-H</given-names></name><name name-style="western"><surname>Sastre-Garau</surname><given-names>X</given-names></name><name name-style="western"><surname>Soumelis</surname><given-names>V</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S</given-names></name></person-group>. <article-title>Characterization of resident and migratory dendritic cells in human lymph nodes</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>(<issue>4</issue>):<fpage>653</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20111457</pub-id><pub-id pub-id-type="pmid">22430490</pub-id><pub-id pub-id-type="pmcid">PMC3328358</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashem</surname><given-names>SW</given-names></name><name name-style="western"><surname>Igyarto</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Gerami-Nejad</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>JA</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>E</given-names></name><etal/></person-group><article-title><italic toggle="yes">Candida albicans</italic> morphology and dendritic cell subsets determine T helper cell differentiation</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>42</volume>(<issue>2</issue>):<fpage>356</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.01.008</pub-id><pub-id pub-id-type="pmid">25680275</pub-id><pub-id pub-id-type="pmcid">PMC4343045</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igy&#225;rt&#243;</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Haley</surname><given-names>K</given-names></name><name name-style="western"><surname>Ortner</surname><given-names>D</given-names></name><name name-style="western"><surname>Bobr</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerami-Nejad</surname><given-names>M</given-names></name><name name-style="western"><surname>Edelson</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>35</volume>(<issue>2</issue>):<fpage>260</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2011.06.005</pub-id><pub-id pub-id-type="pmid">21782478</pub-id><pub-id pub-id-type="pmcid">PMC3163010</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Pattern recognition receptors and inflammation</article-title>. <source>Cell</source> (<year>2010</year>) <volume>140</volume>(<issue>6</issue>):<fpage>805</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>S</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>JP</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Werth</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MW</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>BT</given-names></name><etal/></person-group><article-title>CCR7 and IRF4-dependent dendritic cells regulate lymphatic collecting vessel permeability</article-title>. <source>J Clin Invest</source> (<year>2016</year>) <volume>126</volume>(<issue>4</issue>):<fpage>1581</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1172/JCI84518</pub-id><pub-id pub-id-type="pmid">26999610</pub-id><pub-id pub-id-type="pmcid">PMC4811132</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>F&#246;rster</surname><given-names>R</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A</given-names></name><name name-style="western"><surname>Worbs</surname><given-names>T</given-names></name></person-group>. <article-title>Lymph node homing of T cells and dendritic cells via afferent lymphatics</article-title>. <source>Trends Immunol</source> (<year>2012</year>) <volume>33</volume>(<issue>6</issue>):<fpage>271</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2012.02.007</pub-id><pub-id pub-id-type="pmid">22459312</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>A</given-names></name><name name-style="western"><surname>Worbs</surname><given-names>T</given-names></name><name name-style="western"><surname>Moschovakis</surname><given-names>GL</given-names></name><name name-style="western"><surname>Halle</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>K</given-names></name><name name-style="western"><surname>B&#246;lter</surname><given-names>J</given-names></name><etal/></person-group><article-title>Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration</article-title>. <source>Nat Immunol</source> (<year>2011</year>) <volume>12</volume>(<issue>9</issue>):<fpage>879</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2085</pub-id><pub-id pub-id-type="pmid">21841786</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itano</surname><given-names>AA</given-names></name><name name-style="western"><surname>McSorley</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>RL</given-names></name><name name-style="western"><surname>Ehst</surname><given-names>BD</given-names></name><name name-style="western"><surname>Ingulli</surname><given-names>E</given-names></name><name name-style="western"><surname>Rudensky</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity</article-title>. <source>Immunity</source> (<year>2003</year>) <volume>19</volume>(<issue>1</issue>):<fpage>47</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(03)00175-4</pub-id><pub-id pub-id-type="pmid">12871638</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitali</surname><given-names>C</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Broggi</surname><given-names>A</given-names></name><name name-style="western"><surname>Barresi</surname><given-names>S</given-names></name><name name-style="western"><surname>Zolezzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Bayry</surname><given-names>J</given-names></name><etal/></person-group><article-title>Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells</article-title>. <source>Blood</source> (<year>2012</year>) <volume>120</volume>(<issue>6</issue>):<fpage>1237</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-09-379776</pub-id><pub-id pub-id-type="pmid">22760781</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawiger</surname><given-names>D</given-names></name><name name-style="western"><surname>Inaba</surname><given-names>K</given-names></name><name name-style="western"><surname>Dorsett</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Mahnke</surname><given-names>K</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo</article-title>. <source>J Exp Med</source> (<year>2001</year>) <volume>194</volume>(<issue>6</issue>):<fpage>769</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1084/jem.194.6.769</pub-id><pub-id pub-id-type="pmid">11560993</pub-id><pub-id pub-id-type="pmcid">PMC2195961</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hawiger</surname><given-names>D</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group>. <article-title>Tolerogenic dendritic cells</article-title>. <source>Annu Rev Immunol</source> (<year>2003</year>) <volume>21</volume>(<issue>1</issue>):<fpage>685</fpage>&#8211;<lpage>711</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141040</pub-id><pub-id pub-id-type="pmid">12615891</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></name></person-group><article-title>Th17&#8201;cells in mucosal immunity and tissue inflammation</article-title>. <source>Semin Immunopathol</source> (<year>2010</year>) <volume>32</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1007/s00281-010-0198-8</pub-id><pub-id pub-id-type="pmid">20182729</pub-id><pub-id pub-id-type="pmcid">PMC3424504</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Ostuni</surname><given-names>R</given-names></name><name name-style="western"><surname>Capuano</surname><given-names>G</given-names></name><name name-style="western"><surname>Collini</surname><given-names>M</given-names></name><name name-style="western"><surname>Caccia</surname><given-names>M</given-names></name><name name-style="western"><surname>Ronchi</surname><given-names>AE</given-names></name><etal/></person-group><article-title>CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation</article-title>. <source>Nature</source> (<year>2009</year>) <volume>460</volume>(<issue>7252</issue>):<fpage>264</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nature08118</pub-id><pub-id pub-id-type="pmid">19525933</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Dendritic cell apoptosis in the maintenance of immune tolerance</article-title>. <source>Science</source> (<year>2006</year>) <volume>311</volume>(<issue>5764</issue>):<fpage>1160</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1126/science.1122545</pub-id><pub-id pub-id-type="pmid">16497935</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stranges</surname><given-names>PB</given-names></name><name name-style="western"><surname>Watson</surname><given-names>J</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Choisy-Rossi</surname><given-names>CM</given-names></name><name name-style="western"><surname>Stonebraker</surname><given-names>AC</given-names></name><name name-style="western"><surname>Beighton</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>26</volume>(<issue>5</issue>):<fpage>629</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2007.03.016</pub-id><pub-id pub-id-type="pmid">17509906</pub-id><pub-id pub-id-type="pmcid">PMC2575811</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tubo</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Fife</surname><given-names>BT</given-names></name><name name-style="western"><surname>Pagan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kotov</surname><given-names>DI</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>MF</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MK</given-names></name></person-group><article-title>Most microbe-specific na&#239;ve CD4+ T cells produce memory cells during infection</article-title>. <source>Science</source> (<year>2016</year>) <volume>351</volume>(<issue>6272</issue>):<fpage>511</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1126/science.aad0483</pub-id><pub-id pub-id-type="pmid">26823430</pub-id><pub-id pub-id-type="pmcid">PMC4776317</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name></person-group>. <article-title>Alum: an old dog with new tricks</article-title>. <source>Emerg Microbes Infect</source> (<year>2016</year>) <volume>5</volume>(<issue>3</issue>):<fpage>e25</fpage>.<pub-id pub-id-type="doi">10.1038/emi.2016.40</pub-id><pub-id pub-id-type="pmid">27004761</pub-id><pub-id pub-id-type="pmcid">PMC4820675</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kool</surname><given-names>M</given-names></name><name name-style="western"><surname>P&#233;trilli</surname><given-names>V</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>T</given-names></name><name name-style="western"><surname>Rolaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H</given-names></name><name name-style="western"><surname>van Nimwegen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>(<issue>6</issue>):<fpage>3755</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.6.3755</pub-id><pub-id pub-id-type="pmid">18768827</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>SB</given-names></name><name name-style="western"><surname>Ting</surname><given-names>JP-Y</given-names></name><name name-style="western"><surname>Re</surname><given-names>F</given-names></name></person-group><article-title>Cutting edge: inflammasome activation by alum and alum&#8217;s adjuvant effect are mediated by NLRP3</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>(<issue>1</issue>):<fpage>17</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.1.17</pub-id><pub-id pub-id-type="pmid">18566365</pub-id><pub-id pub-id-type="pmcid">PMC2587213</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franchi</surname><given-names>L</given-names></name><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>G</given-names></name></person-group><article-title>The Nlrp3 inflammasome is critical for aluminum hydroxide-mediated IL-1&#946; secretion but dispensable for adjuvant activity</article-title>. <source>Eur J Immunol</source> (<year>2008</year>) <volume>38</volume>(<issue>8</issue>):<fpage>2085</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200838549</pub-id><pub-id pub-id-type="pmid">18624356</pub-id><pub-id pub-id-type="pmcid">PMC2759997</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marichal</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohata</surname><given-names>K</given-names></name><name name-style="western"><surname>Bedoret</surname><given-names>D</given-names></name><name name-style="western"><surname>Mesnil</surname><given-names>C</given-names></name><name name-style="western"><surname>Sabatel</surname><given-names>C</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K</given-names></name><etal/></person-group><article-title>DNA released from dying host cells mediates aluminum adjuvant activity</article-title>. <source>Nat Med</source> (<year>2011</year>) <volume>17</volume>(<issue>8</issue>):<fpage>996</fpage>&#8211;<lpage>1002</lpage>.<pub-id pub-id-type="doi">10.1038/nm.2403</pub-id><pub-id pub-id-type="pmid">21765404</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavin</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hoebe</surname><given-names>K</given-names></name><name name-style="western"><surname>Duong</surname><given-names>B</given-names></name><name name-style="western"><surname>Ota</surname><given-names>T</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Beutler</surname><given-names>B</given-names></name><etal/></person-group><article-title>Adjuvant-enhanced antibody receptor signaling</article-title>. <source>Science</source> (<year>2006</year>) <volume>314</volume>:<fpage>1936</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.1135299</pub-id><pub-id pub-id-type="pmid">17185603</pub-id><pub-id pub-id-type="pmcid">PMC1868398</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>AS</given-names></name><name name-style="western"><surname>Munks</surname><given-names>MW</given-names></name><name name-style="western"><surname>MacLeod</surname><given-names>MKL</given-names></name><name name-style="western"><surname>Fleenor</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Van Rooijen</surname><given-names>N</given-names></name><name name-style="western"><surname>Kappler</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>(<issue>7</issue>):<fpage>4403</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0900164</pub-id><pub-id pub-id-type="pmid">19734227</pub-id><pub-id pub-id-type="pmcid">PMC2912728</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khameneh</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Ho</surname><given-names>AWS</given-names></name><name name-style="western"><surname>Spreafico</surname><given-names>R</given-names></name><name name-style="western"><surname>Derks</surname><given-names>H</given-names></name><name name-style="western"><surname>Quek</surname><given-names>HQY</given-names></name><name name-style="western"><surname>Mortellaro</surname><given-names>A</given-names></name></person-group><article-title>The Syk&#8211;NFAT&#8211;IL-2 pathway in dendritic cells is required for optimal sterile immunity elicited by alum adjuvants</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>(<issue>1</issue>):<fpage>196</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1600420</pub-id><pub-id pub-id-type="pmid">27895176</pub-id><pub-id pub-id-type="pmcid">PMC5164880</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>NP</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>A</given-names></name><name name-style="western"><surname>Buonsanti</surname><given-names>C</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1038/srep19570</pub-id><pub-id pub-id-type="pmid">26791076</pub-id><pub-id pub-id-type="pmcid">PMC4726129</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantisani</surname><given-names>R</given-names></name><name name-style="western"><surname>Pezzicoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Cioncada</surname><given-names>R</given-names></name><name name-style="western"><surname>Malzone</surname><given-names>C</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name><name name-style="western"><surname>D&#8217;Oro</surname><given-names>U</given-names></name><etal/></person-group><article-title>Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>(<issue>4</issue>):<fpage>1717</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1400623</pub-id><pub-id pub-id-type="pmid">25589069</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cioncada</surname><given-names>R</given-names></name><name name-style="western"><surname>Maddaluno</surname><given-names>M</given-names></name><name name-style="western"><surname>Vo</surname><given-names>HTM</given-names></name><name name-style="western"><surname>Woodruff</surname><given-names>M</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sammicheli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells</article-title>. <source>PLoS One</source> (<year>2017</year>) <volume>12</volume>(<issue>10</issue>):<fpage>e0185843</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0185843</pub-id><pub-id pub-id-type="pmid">29088224</pub-id><pub-id pub-id-type="pmcid">PMC5663329</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gogolak</surname><given-names>P</given-names></name><name name-style="western"><surname>Pazmandi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kis-Toth</surname><given-names>K</given-names></name><name name-style="western"><surname>Riedl</surname><given-names>K</given-names></name><name name-style="western"><surname>Wizel</surname><given-names>B</given-names></name><etal/></person-group><article-title>The two-component adjuvant IC31<sup>&#174;</sup> boosts type I interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>(<issue>2</issue>).<pub-id pub-id-type="doi">10.1371/journal.pone.0055264</pub-id><pub-id pub-id-type="pmid">23405128</pub-id><pub-id pub-id-type="pmcid">PMC3566214</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekiya</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamagishi</surname><given-names>J</given-names></name><name name-style="western"><surname>Gray</surname><given-names>JHV</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>PG</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W</given-names></name><etal/></person-group><article-title>PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+T cell responses</article-title>. <source>Biomaterials</source> (<year>2017</year>) <volume>137</volume>:<fpage>61</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.05.018</pub-id><pub-id pub-id-type="pmid">28544973</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halliday</surname><given-names>A</given-names></name><name name-style="western"><surname>Turner</surname><given-names>JD</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>A</given-names></name><name name-style="western"><surname>Bates</surname><given-names>PA</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>MJ</given-names></name></person-group>. <article-title>The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in <italic toggle="yes">Leishmania major</italic> and <italic toggle="yes">Brugia malayi</italic> murine vaccine models</article-title>. <source>Parasit Vectors</source> (<year>2016</year>) <volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1186/s13071-016-1381-0</pub-id><pub-id pub-id-type="pmid">26897363</pub-id><pub-id pub-id-type="pmcid">PMC4761161</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tatematsu</surname><given-names>M</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>N</given-names></name><name name-style="western"><surname>Morii-Sakai</surname><given-names>A</given-names></name><etal/></person-group><article-title>Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo</article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1038/ncomms7280</pub-id><pub-id pub-id-type="pmid">25692975</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Egelston</surname><given-names>C</given-names></name><name name-style="western"><surname>Gagnon</surname><given-names>S</given-names></name><name name-style="western"><surname>Sui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Belyakov</surname><given-names>IM</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice</article-title>. <source>J Clin Invest</source> (<year>2010</year>) <volume>120</volume>(<issue>2</issue>):<fpage>607</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1172/JCI39293</pub-id><pub-id pub-id-type="pmid">20101095</pub-id><pub-id pub-id-type="pmcid">PMC2811160</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D</given-names></name><name name-style="western"><surname>Orr</surname><given-names>MT</given-names></name></person-group>. <article-title>The science of vaccine adjuvants: advances in TLR4 ligand adjuvants</article-title>. <source>Curr Opin Immunol</source> (<year>2016</year>) <volume>41</volume>:<fpage>85</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2016.06.007</pub-id><pub-id pub-id-type="pmid">27392183</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>JR</given-names></name></person-group>. <article-title>Functional properties of flagellin as a stimulator of innate immunity</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1038/srep18379</pub-id><pub-id pub-id-type="pmid">26755208</pub-id><pub-id pub-id-type="pmcid">PMC4709591</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buonsanti</surname><given-names>C</given-names></name><name name-style="western"><surname>Balocchi</surname><given-names>C</given-names></name><name name-style="western"><surname>Harfouche</surname><given-names>C</given-names></name><name name-style="western"><surname>Corrente</surname><given-names>F</given-names></name><name name-style="western"><surname>Galli Stampino</surname><given-names>L</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>F</given-names></name><etal/></person-group><article-title>Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1038/srep29063</pub-id><pub-id pub-id-type="pmid">27439378</pub-id><pub-id pub-id-type="pmcid">PMC4954951</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>MR</given-names></name><name name-style="western"><surname>Soldaini</surname><given-names>E</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>RP</given-names></name><name name-style="western"><surname>Fiaschi</surname><given-names>L</given-names></name><name name-style="western"><surname>Cartocci</surname><given-names>E</given-names></name><etal/></person-group><article-title>Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2015</year>) <volume>112</volume>(<issue>12</issue>):<fpage>201424924</fpage>.<pub-id pub-id-type="doi">10.1073/pnas.1424924112</pub-id><pub-id pub-id-type="pmid">25775551</pub-id><pub-id pub-id-type="pmcid">PMC4378396</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hoeven</surname><given-names>N</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name><name name-style="western"><surname>Granger</surname><given-names>B</given-names></name><name name-style="western"><surname>Evers</surname><given-names>T</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>SW</given-names></name><name name-style="western"><surname>Nana</surname><given-names>GI</given-names></name><etal/></person-group><article-title>A Formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1038/srep46426</pub-id><pub-id pub-id-type="pmid">28429728</pub-id><pub-id pub-id-type="pmcid">PMC5399443</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>YC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SJ</given-names></name></person-group>. <article-title>A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1038/srep12578</pub-id><pub-id pub-id-type="pmid">26215533</pub-id><pub-id pub-id-type="pmcid">PMC4517169</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orr</surname><given-names>MT</given-names></name><name name-style="western"><surname>Beebe</surname><given-names>EA</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>TE</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><etal/></person-group><article-title>A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>1</issue>):<fpage>e83884</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0083884</pub-id><pub-id pub-id-type="pmid">24404140</pub-id><pub-id pub-id-type="pmcid">PMC3880254</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>CD</given-names></name><name name-style="western"><surname>Varma</surname><given-names>TK</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>JB</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>A</given-names></name><name name-style="western"><surname>Driver</surname><given-names>B</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>ER</given-names></name></person-group>. <article-title>The toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection</article-title>. <source>Infect Immun</source> (<year>2011</year>) <volume>79</volume>(<issue>9</issue>):<fpage>3576</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00022-11</pub-id><pub-id pub-id-type="pmid">21646453</pub-id><pub-id pub-id-type="pmcid">PMC3165493</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>W</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>NS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>H</given-names></name><name name-style="western"><surname>Kleinstein</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kaech</surname><given-names>SM</given-names></name></person-group>. <article-title>TLR4 ligands lipopolysaccharide and monophosphoryl lipid A differentially regulate effector and memory CD8+ T cell differentiation</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>(<issue>9</issue>):<fpage>4221</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1302569</pub-id><pub-id pub-id-type="pmid">24659688</pub-id><pub-id pub-id-type="pmcid">PMC4071140</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdy</surname><given-names>S</given-names></name><name name-style="western"><surname>Molavi</surname><given-names>O</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Haddadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Alshamsan</surname><given-names>A</given-names></name><name name-style="western"><surname>Gobti</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Co-delivery of cancer-associated antigen and toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+T cell-mediated anti-tumor immunity</article-title>. <source>Vaccine</source> (<year>2008</year>) <volume>26</volume>(<issue>39</issue>):<fpage>5046</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.035</pub-id><pub-id pub-id-type="pmid">18680779</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granucci</surname><given-names>F</given-names></name><name name-style="western"><surname>Vizzardelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Pavelka</surname><given-names>N</given-names></name><name name-style="western"><surname>Feau</surname><given-names>S</given-names></name><name name-style="western"><surname>Persico</surname><given-names>M</given-names></name><name name-style="western"><surname>Virzi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inducible IL-2 production by dendritic cells revealed by global gene expression analysis</article-title>. <source>Nat Immunol</source> (<year>2001</year>) <volume>2</volume>(<issue>9</issue>):<fpage>882</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/ni0901-882</pub-id><pub-id pub-id-type="pmid">11526406</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Granucci</surname><given-names>F</given-names></name></person-group>. <article-title>Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs)</article-title>. <source>Eur J Immunol</source> (<year>2012</year>) <volume>42</volume>(<issue>8</issue>):<fpage>1924</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201242580</pub-id><pub-id pub-id-type="pmid">22706795</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wuest</surname><given-names>SC</given-names></name><name name-style="western"><surname>Edwan</surname><given-names>JH</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JF</given-names></name><name name-style="western"><surname>Han</surname><given-names>S</given-names></name><name name-style="western"><surname>Perry</surname><given-names>JS</given-names></name><name name-style="western"><surname>Cartagena</surname><given-names>CM</given-names></name><etal/></person-group><article-title>A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy</article-title>. <source>Nat Med</source> (<year>2011</year>) <volume>17</volume>(<issue>5</issue>):<fpage>604</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nm.2365</pub-id><pub-id pub-id-type="pmid">21532597</pub-id><pub-id pub-id-type="pmcid">PMC3089658</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A</given-names></name></person-group>. <article-title>NFAT, immunity and cancer: a transcription factor comes of age</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>(<issue>9</issue>):<fpage>645</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1038/nri2818</pub-id><pub-id pub-id-type="pmid">20725108</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodridge</surname><given-names>HS</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>RM</given-names></name><name name-style="western"><surname>Underhill</surname><given-names>DM</given-names></name></person-group>. <article-title>Dectin-1 stimulation by <italic toggle="yes">Candida albicans</italic> yeast or zymosan triggers NFAT activation in macrophages and dendritic cells</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>5</issue>):<fpage>3107</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.5.3107</pub-id><pub-id pub-id-type="pmid">17312158</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>MB</given-names></name><name name-style="western"><surname>Aliprantis</surname><given-names>A</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Glimcher</surname><given-names>LH</given-names></name></person-group>. <article-title>Calcineurin regulates innate antifungal immunity in neutrophils</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>(<issue>5</issue>):<fpage>923</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20092531</pub-id><pub-id pub-id-type="pmid">20421389</pub-id><pub-id pub-id-type="pmcid">PMC2867274</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yonekawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>E</given-names></name><name name-style="western"><surname>Suzukawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>(<issue>3</issue>):<fpage>402</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.08.005</pub-id><pub-id pub-id-type="pmid">25176311</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>S</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazon Moya</surname><given-names>M</given-names></name><name name-style="western"><surname>Marzola</surname><given-names>V</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>B</given-names></name><name name-style="western"><surname>Reed</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to <italic toggle="yes">Aspergillus fumigatus</italic></article-title>. <source>EMBO Mol Med</source> (<year>2015</year>) <volume>7</volume>(<issue>3</issue>):<fpage>e201404556</fpage>.<pub-id pub-id-type="doi">10.15252/emmm.201404556</pub-id><pub-id pub-id-type="pmid">25637383</pub-id><pub-id pub-id-type="pmcid">PMC4364943</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santus</surname><given-names>W</given-names></name><name name-style="western"><surname>Barresi</surname><given-names>S</given-names></name><name name-style="western"><surname>Mingozzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Broggi</surname><given-names>A</given-names></name><name name-style="western"><surname>Orlandi</surname><given-names>I</given-names></name><name name-style="western"><surname>Stamerra</surname><given-names>G</given-names></name><etal/></person-group><article-title>Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems</article-title>. <source>Sci Immunol</source> (<year>2017</year>) <volume>2</volume>(<issue>15</issue>):<fpage>eaan2725</fpage>.<pub-id pub-id-type="doi">10.1126/sciimmunol.aan2725</pub-id><pub-id pub-id-type="pmid">28939652</pub-id><pub-id pub-id-type="pmcid">PMC5682945</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Spreafico</surname><given-names>R</given-names></name><name name-style="western"><surname>Bodio</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Gioia</surname><given-names>M</given-names></name><name name-style="western"><surname>Cigni</surname><given-names>C</given-names></name><name name-style="western"><surname>Broggi</surname><given-names>A</given-names></name><etal/></person-group><article-title>IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions</article-title>. <source>Cell Rep</source> (<year>2013</year>) <volume>4</volume>(<issue>6</issue>):<fpage>1235</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1016/j.celrep.2013.08.021</pub-id><pub-id pub-id-type="pmid">24055061</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granucci</surname><given-names>F</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Pavelka</surname><given-names>N</given-names></name><name name-style="western"><surname>Van Dommelen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Andoniou</surname><given-names>CE</given-names></name><name name-style="western"><surname>Belardelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>A contribution of mouse dendritic cell-derived IL-2 for NK cell activation</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>200</volume>(<issue>3</issue>):<fpage>287</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20040370</pub-id><pub-id pub-id-type="pmid">15289500</pub-id><pub-id pub-id-type="pmcid">PMC2211974</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Ostuni</surname><given-names>R</given-names></name><name name-style="western"><surname>Barresi</surname><given-names>S</given-names></name><name name-style="western"><surname>Di Gioia</surname><given-names>M</given-names></name><name name-style="western"><surname>Broggi</surname><given-names>A</given-names></name><name name-style="western"><surname>Costa</surname><given-names>B</given-names></name><etal/></person-group><article-title>CD14 and NFAT mediate lipopolysaccharide- induced skin edema formation in mice</article-title>. <source>J Clin Invest</source> (<year>2012</year>) <volume>122</volume>(<issue>5</issue>):<fpage>1747</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1172/JCI60688</pub-id><pub-id pub-id-type="pmid">22466648</pub-id><pub-id pub-id-type="pmcid">PMC3336986</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Legler</surname><given-names>DF</given-names></name><name name-style="western"><surname>Krause</surname><given-names>P</given-names></name><name name-style="western"><surname>Scandella</surname><given-names>E</given-names></name><name name-style="western"><surname>Singer</surname><given-names>E</given-names></name><name name-style="western"><surname>Groettrup</surname><given-names>M</given-names></name></person-group>. <article-title>Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>176</volume>(<issue>2</issue>):<fpage>966</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.176.2.966</pub-id><pub-id pub-id-type="pmid">16393982</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kastenm&#252;ller</surname><given-names>W</given-names></name><name name-style="western"><surname>Torabi-Parizi</surname><given-names>P</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>N</given-names></name><name name-style="western"><surname>L&#228;mmermann</surname><given-names>T</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group>. <article-title>A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread</article-title>. <source>Cell</source> (<year>2012</year>) <volume>150</volume>(<issue>6</issue>):<fpage>1235</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2012.07.021</pub-id><pub-id pub-id-type="pmid">22980983</pub-id><pub-id pub-id-type="pmcid">PMC3514884</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>SF</given-names></name><name name-style="western"><surname>Lukacs-Kornek</surname><given-names>V</given-names></name><name name-style="western"><surname>Kuligowski</surname><given-names>MP</given-names></name><name name-style="western"><surname>Pitcher</surname><given-names>LA</given-names></name><name name-style="western"><surname>Degn</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>(<issue>5</issue>):<fpage>427</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1856</pub-id><pub-id pub-id-type="pmid">20305659</pub-id><pub-id pub-id-type="pmcid">PMC3424101</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roozendaal</surname><given-names>R</given-names></name><name name-style="western"><surname>Mempel</surname><given-names>TR</given-names></name><name name-style="western"><surname>Pitcher</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>SF</given-names></name><name name-style="western"><surname>Verschoor</surname><given-names>A</given-names></name><name name-style="western"><surname>Mebius</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Conduits mediate transport of low-molecular-weight antigen to lymph node follicles</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>30</volume>(<issue>2</issue>):<fpage>264</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2008.12.014</pub-id><pub-id pub-id-type="pmid">19185517</pub-id><pub-id pub-id-type="pmcid">PMC2699624</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Torabi-Parizi</surname><given-names>P</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group>. <article-title>Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>42</volume>(<issue>1</issue>):<fpage>172</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.024</pub-id><pub-id pub-id-type="pmid">25607462</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Kastenmuller</surname><given-names>W</given-names></name><name name-style="western"><surname>Ifrim</surname><given-names>I</given-names></name><name name-style="western"><surname>Kabat</surname><given-names>J</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group>. <article-title>Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>(<issue>2</issue>):<fpage>364</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.07.011</pub-id><pub-id pub-id-type="pmid">22863836</pub-id><pub-id pub-id-type="pmcid">PMC3514885</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iannacone</surname><given-names>M</given-names></name><name name-style="western"><surname>Moseman</surname><given-names>EA</given-names></name><name name-style="western"><surname>Tonti</surname><given-names>E</given-names></name><name name-style="western"><surname>Bosurgi</surname><given-names>L</given-names></name><name name-style="western"><surname>Junt</surname><given-names>T</given-names></name><name name-style="western"><surname>Henrickson</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus</article-title>. <source>Nature</source> (<year>2010</year>) <volume>465</volume>(<issue>7301</issue>):<fpage>1079</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1038/nature09118</pub-id><pub-id pub-id-type="pmid">20577213</pub-id><pub-id pub-id-type="pmcid">PMC2892812</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sixt</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanazawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Selg</surname><given-names>M</given-names></name><name name-style="western"><surname>Samson</surname><given-names>T</given-names></name><name name-style="western"><surname>Roos</surname><given-names>G</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>DP</given-names></name><etal/></person-group><article-title>The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node</article-title>. <source>Immunity</source> (<year>2005</year>) <volume>22</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2004.11.013</pub-id><pub-id pub-id-type="pmid">15664156</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrell</surname><given-names>HE</given-names></name><name name-style="western"><surname>Davis-Poynter</surname><given-names>N</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>K</given-names></name><name name-style="western"><surname>Lawler</surname><given-names>C</given-names></name><name name-style="western"><surname>Dolken</surname><given-names>L</given-names></name><name name-style="western"><surname>Mach</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lymph node macrophages restrict murine cytomegalovirus dissemination</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>89</volume>(<issue>14</issue>):<fpage>7147</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.00480-15</pub-id><pub-id pub-id-type="pmid">25926638</pub-id><pub-id pub-id-type="pmcid">PMC4473555</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frederico</surname><given-names>B</given-names></name><name name-style="western"><surname>Chao</surname><given-names>B</given-names></name><name name-style="western"><surname>Lawler</surname><given-names>C</given-names></name><name name-style="western"><surname>May</surname><given-names>JS</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>PG</given-names></name></person-group>. <article-title>Subcapsular sinus macrophages limit acute gammaherpesvirus dissemination</article-title>. <source>J Gen Virol</source> (<year>2015</year>) <volume>96</volume>(<issue>8</issue>):<fpage>2314</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1099/vir.0.000140</pub-id><pub-id pub-id-type="pmid">25872742</pub-id><pub-id pub-id-type="pmcid">PMC4681069</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomura</surname><given-names>M</given-names></name><name name-style="western"><surname>Hata</surname><given-names>A</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>S</given-names></name><name name-style="western"><surname>Shand</surname><given-names>FH</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ikebuchi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tracking and quantification of dendritic cell migration and antigen trafficking between the skin and lymph nodes</article-title>. <source>Sci Rep</source> (<year>2014</year>) <volume>4</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1038/srep06030</pub-id><pub-id pub-id-type="pmid">25112380</pub-id><pub-id pub-id-type="pmcid">PMC4129424</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kissenpfennig</surname><given-names>A</given-names></name><name name-style="western"><surname>Henri</surname><given-names>S</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><name name-style="western"><surname>Laplace-Builh&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>P</given-names></name><name name-style="western"><surname>Romani</surname><given-names>N</given-names></name><etal/></person-group><article-title>Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areasdistinct from slower migrating Langerhans cells</article-title>. <source>Immunity</source> (<year>2005</year>) <volume>22</volume>(<issue>5</issue>):<fpage>643</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2005.04.004</pub-id><pub-id pub-id-type="pmid">15894281</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radtke</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kastenm&#252;ller</surname><given-names>W</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Tse</surname><given-names>SW</given-names></name><name name-style="western"><surname>Sinnis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Lymph-node resident CD8a+ dendritic cells capture antigens from migratory malaria sporozoites and induce CD8+ T cell responses</article-title>. <source>PLoS Pathog</source> (<year>2015</year>) <volume>11</volume>(<issue>2</issue>):<fpage>e1004637</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004637</pub-id><pub-id pub-id-type="pmid">25658939</pub-id><pub-id pub-id-type="pmcid">PMC4450069</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iezzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Fr&#246;hlich</surname><given-names>A</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>B</given-names></name><name name-style="western"><surname>Ampenberger</surname><given-names>F</given-names></name><name name-style="western"><surname>Saeland</surname><given-names>S</given-names></name><name name-style="western"><surname>Glaichenhaus</surname><given-names>N</given-names></name><etal/></person-group><article-title>Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after <italic toggle="yes">Leishmania major</italic> infection</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>177</volume>(<issue>2</issue>):<fpage>1250</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.177.2.1250</pub-id><pub-id pub-id-type="pmid">16818784</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>WR</given-names></name><name name-style="western"><surname>Belz</surname><given-names>GT</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>GM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CM</given-names></name><name name-style="western"><surname>Forehan</surname><given-names>SP</given-names></name><name name-style="western"><surname>Parish</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens</article-title>. <source>Immunol Rev</source> (<year>2004</year>) <volume>199</volume>:<fpage>9</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00142.x</pub-id><pub-id pub-id-type="pmid">15233723</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thacker</surname><given-names>RI</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>EM</given-names></name></person-group>. <article-title>Cross-presentation of cell-associated antigens by mouse splenic dendritic cell populations</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>3</volume>:<fpage>41</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00041</pub-id><pub-id pub-id-type="pmid">22566924</pub-id><pub-id pub-id-type="pmcid">PMC3342388</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewitz</surname><given-names>A</given-names></name><name name-style="western"><surname>Eickhoff</surname><given-names>S</given-names></name><name name-style="western"><surname>D&#228;hling</surname><given-names>S</given-names></name><name name-style="western"><surname>Quast</surname><given-names>T</given-names></name><name name-style="western"><surname>Bedoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Kroczek</surname><given-names>RA</given-names></name><etal/></person-group><article-title>CD8+T cells orchestrate pDC-XCR1+dendritic cell spatial and functional cooperativity to optimize priming</article-title>. <source>Immunity</source> (<year>2017</year>) <volume>46</volume>(<issue>2</issue>):<fpage>205</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2017.01.003</pub-id><pub-id pub-id-type="pmid">28190711</pub-id><pub-id pub-id-type="pmcid">PMC5362251</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allan</surname><given-names>RS</given-names></name><name name-style="western"><surname>Waithman</surname><given-names>J</given-names></name><name name-style="western"><surname>Bedoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CM</given-names></name><name name-style="western"><surname>Villadangos</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>25</volume>(<issue>1</issue>):<fpage>153</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2006.04.017</pub-id><pub-id pub-id-type="pmid">16860764</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mount</surname><given-names>AM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kupresanin</surname><given-names>F</given-names></name><name name-style="western"><surname>Stoermer</surname><given-names>K</given-names></name><name name-style="western"><surname>Heath</surname><given-names>WR</given-names></name><name name-style="western"><surname>Belz</surname><given-names>GT</given-names></name></person-group>. <article-title>Multiple dendritic cell populations activate CD4+ T cells after viral stimulation</article-title>. <source>PLoS One</source> (<year>2008</year>) <volume>3</volume>(<issue>2</issue>):<fpage>e1691</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0001691</pub-id><pub-id pub-id-type="pmid">18301768</pub-id><pub-id pub-id-type="pmcid">PMC2253497</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>PG</given-names></name><name name-style="western"><surname>Waithman</surname><given-names>J</given-names></name><name name-style="western"><surname>Eidsmo</surname><given-names>L</given-names></name><name name-style="western"><surname>Wakim</surname><given-names>L</given-names></name><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cross-presentation of viral and self antigens by skin-derived CD103+dendritic cells</article-title>. <source>Nat Immunol</source> (<year>2009</year>) <volume>10</volume>(<issue>5</issue>):<fpage>488</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1724</pub-id><pub-id pub-id-type="pmid">19349986</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitano</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>C</given-names></name><name name-style="western"><surname>Takumi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ikeno</surname><given-names>T</given-names></name><name name-style="western"><surname>Hemmi</surname><given-names>H</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2016</year>) <volume>113</volume>(<issue>4</issue>):<fpage>1044</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1513607113</pub-id><pub-id pub-id-type="pmid">26755602</pub-id><pub-id pub-id-type="pmcid">PMC4743831</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waithman</surname><given-names>J</given-names></name><name name-style="western"><surname>Zanker</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>K</given-names></name><name name-style="western"><surname>Oveissi</surname><given-names>S</given-names></name><name name-style="western"><surname>Wylie</surname><given-names>B</given-names></name><name name-style="western"><surname>Ng</surname><given-names>R</given-names></name><etal/></person-group><article-title>Resident CD8+ and migratory CD103+ dendritic cells control CD8 T cell immunity during acute influenza infection</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>(<issue>6</issue>):<fpage>e66136</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0066136</pub-id><pub-id pub-id-type="pmid">23750278</pub-id><pub-id pub-id-type="pmcid">PMC3672151</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haniffa</surname><given-names>M</given-names></name><name name-style="western"><surname>Shin</surname><given-names>A</given-names></name><name name-style="western"><surname>Bigley</surname><given-names>V</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>N</given-names></name><name name-style="western"><surname>Teo</surname><given-names>P</given-names></name><name name-style="western"><surname>See</surname><given-names>P</given-names></name><etal/></person-group><article-title>Human tissues contain CD141hiCross-presenting dendritic cells with functional homology to mouse CD103+nonlymphoid dendritic cells</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>(<issue>1</issue>):<fpage>60</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.04.012</pub-id><pub-id pub-id-type="pmid">22795876</pub-id><pub-id pub-id-type="pmcid">PMC3476529</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edelson</surname><given-names>BT</given-names></name><name name-style="western"><surname>KC</surname><given-names>W</given-names></name><name name-style="western"><surname>Juang</surname><given-names>R</given-names></name><name name-style="western"><surname>Kohyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Benoit</surname><given-names>LA</given-names></name><name name-style="western"><surname>Klekotka</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Peripheral CD103 <sup>+</sup> dendritic cells form a unified subset developmentally related to CD8&#945; <sup>+</sup> conventional dendritic cells</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>(<issue>4</issue>):<fpage>823</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20091627</pub-id><pub-id pub-id-type="pmid">20351058</pub-id><pub-id pub-id-type="pmcid">PMC2856032</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorner</surname><given-names>BG</given-names></name><name name-style="western"><surname>Dorner</surname><given-names>MB</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Opitz</surname><given-names>C</given-names></name><name name-style="western"><surname>Mora</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#252;ttler</surname><given-names>S</given-names></name><etal/></person-group><article-title>Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>31</volume>(<issue>5</issue>):<fpage>823</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2009.08.027</pub-id><pub-id pub-id-type="pmid">19913446</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravindran</surname><given-names>R</given-names></name><name name-style="western"><surname>Rusch</surname><given-names>L</given-names></name><name name-style="western"><surname>Itano</surname><given-names>A</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MK</given-names></name><name name-style="western"><surname>McSorley</surname><given-names>SJ</given-names></name></person-group>. <article-title>CCR6-dependent recruitment of blood phagocytes is necessary for rapid CD4 T cell responses to local bacterial infection</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>(<issue>29</issue>):<fpage>12075</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0701363104</pub-id><pub-id pub-id-type="pmid">17615242</pub-id><pub-id pub-id-type="pmcid">PMC1907313</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van</surname><given-names>VQ</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>S</given-names></name><name name-style="western"><surname>Bouguermouh</surname><given-names>S</given-names></name><name name-style="western"><surname>Gautier</surname><given-names>P</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>M</given-names></name><name name-style="western"><surname>Levesque</surname><given-names>M</given-names></name><etal/></person-group><article-title>Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs</article-title>. <source>EMBO J</source> (<year>2006</year>) <volume>25</volume>(<issue>23</issue>):<fpage>5560</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/sj.emboj.7601415</pub-id><pub-id pub-id-type="pmid">17093498</pub-id><pub-id pub-id-type="pmcid">PMC1679770</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoitzner</surname><given-names>P</given-names></name><name name-style="western"><surname>Green</surname><given-names>LK</given-names></name><name name-style="western"><surname>Jung</surname><given-names>JY</given-names></name><name name-style="western"><surname>Price</surname><given-names>KM</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>CH</given-names></name><name name-style="western"><surname>Malissen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tumor immunotherapy by epicutaneous immunization requires Langerhans cells</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>(<issue>3</issue>):<fpage>1991</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.180.3.1991</pub-id><pub-id pub-id-type="pmid">18209098</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Bursch</surname><given-names>LS</given-names></name><name name-style="western"><surname>Kissenpfennig</surname><given-names>A</given-names></name><name name-style="western"><surname>Malissen</surname><given-names>B</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Hogquist</surname><given-names>KA</given-names></name></person-group>. <article-title>Langerin expressing cells promote skin immune responses under defined conditions</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>(<issue>7</issue>):<fpage>4722</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.180.7.4722</pub-id><pub-id pub-id-type="pmid">18354196</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seneschal</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Kupper</surname><given-names>TS</given-names></name></person-group>. <article-title>Langerin + dermal DC, but not Langerhans cells, are required for effective CD8-mediated immune responses after skin scarification with vaccinia virus</article-title>. <source>J Invest Dermatol</source> (<year>2014</year>) <volume>134</volume>(<issue>3</issue>):<fpage>686</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1038/jid.2013.418</pub-id><pub-id pub-id-type="pmid">24126845</pub-id><pub-id pub-id-type="pmcid">PMC3945525</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>DH</given-names></name></person-group><article-title>Langerhans cells: not your average dendritic cell</article-title>. <source>Trends Immunol</source> (<year>2010</year>) <volume>31</volume>(<issue>12</issue>):<fpage>437</fpage><pub-id pub-id-type="doi">10.1016/j.it.2010.10.003</pub-id><pub-id pub-id-type="pmid">21075684</pub-id><pub-id pub-id-type="pmcid">PMC3056439</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igyarto</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Jenison</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dudda</surname><given-names>JC</given-names></name><name name-style="western"><surname>Roers</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>W</given-names></name><name name-style="western"><surname>Koni</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Langerhans cells suppress contact hypersensitivity responses via cognate CD4 interaction and Langerhans cell-derived IL-10</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>(<issue>8</issue>):<fpage>5085</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0901884</pub-id><pub-id pub-id-type="pmid">19801524</pub-id><pub-id pub-id-type="pmcid">PMC3131075</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutyambizi</surname><given-names>K</given-names></name><name name-style="western"><surname>Berger</surname><given-names>CL</given-names></name><name name-style="western"><surname>Edelson</surname><given-names>RL</given-names></name></person-group>. <article-title>The balance between immunity and tolerance: the role of Langerhans cells</article-title>. <source>Cell Mol Life Sci</source> (<year>2009</year>) <volume>66</volume>(<issue>5</issue>):<fpage>831</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1007/s00018-008-8470-y</pub-id><pub-id pub-id-type="pmid">19002380</pub-id><pub-id pub-id-type="pmcid">PMC4075167</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eickhoff</surname><given-names>S</given-names></name><name name-style="western"><surname>Brewitz</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Klauschen</surname><given-names>F</given-names></name><name name-style="western"><surname>Komander</surname><given-names>K</given-names></name><name name-style="western"><surname>Hemmi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions</article-title>. <source>Cell</source> (<year>2015</year>) <volume>162</volume>(<issue>6</issue>):<fpage>1322</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2015.08.004</pub-id><pub-id pub-id-type="pmid">26296422</pub-id><pub-id pub-id-type="pmcid">PMC4567961</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allenspach</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lemos</surname><given-names>MP</given-names></name><name name-style="western"><surname>Porrett</surname><given-names>PM</given-names></name><name name-style="western"><surname>Turka</surname><given-names>LA</given-names></name><name name-style="western"><surname>Laufer</surname><given-names>TM</given-names></name></person-group>. <article-title>Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>29</volume>(<issue>5</issue>):<fpage>795</fpage>&#8211;<lpage>806</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2008.08.013</pub-id><pub-id pub-id-type="pmid">18951047</pub-id><pub-id pub-id-type="pmcid">PMC2746692</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>D</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>L</given-names></name><name name-style="western"><surname>Kepler</surname><given-names>TB</given-names></name><name name-style="western"><surname>Parker</surname><given-names>I</given-names></name><name name-style="western"><surname>Cahalan</surname><given-names>MD</given-names></name></person-group>. <article-title>Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1- and Th2-polarizing adjuvants</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2010</year>) <volume>107</volume>(<issue>18</issue>):<fpage>8334</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0912817107</pub-id><pub-id pub-id-type="pmid">20404167</pub-id><pub-id pub-id-type="pmcid">PMC2889549</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonialli</surname><given-names>R</given-names></name><name name-style="western"><surname>Sulczewski</surname><given-names>FB</given-names></name><name name-style="western"><surname>Amorim</surname><given-names>KNDS</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>BDS</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>NS</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>MM</given-names></name><etal/></person-group><article-title>CpG oligodeoxinucleotides and flagellin modulate the immune response to antigens targeted to CD8&#945;+and CD8&#945;- conventional dendritic cell subsets</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<fpage>1727</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.01727</pub-id><pub-id pub-id-type="pmid">29255470</pub-id><pub-id pub-id-type="pmcid">PMC5723008</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosalia</surname><given-names>RA</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>van Duikeren</surname><given-names>S</given-names></name><name name-style="western"><surname>Tromp</surname><given-names>AT</given-names></name><name name-style="western"><surname>Silva</surname><given-names>AL</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name><etal/></person-group><article-title>CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses</article-title>. <source>Biomaterials</source> (<year>2015</year>) <volume>40</volume>:<fpage>88</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.10.053</pub-id><pub-id pub-id-type="pmid">25465442</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trumpfheller</surname><given-names>C</given-names></name><name name-style="western"><surname>Finke</surname><given-names>JS</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>CB</given-names></name><name name-style="western"><surname>Moran</surname><given-names>TM</given-names></name><name name-style="western"><surname>Moltedo</surname><given-names>B</given-names></name><name name-style="western"><surname>Soares</surname><given-names>H</given-names></name><etal/></person-group><article-title>Intensified and protective CD4 <sup>+</sup> T cell immunity in mice with anti&#8211;dendritic cell HIV gag fusion antibody vaccine</article-title>. <source>J Exp Med</source> (<year>2006</year>) <volume>203</volume>(<issue>3</issue>):<fpage>607</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20052005</pub-id><pub-id pub-id-type="pmid">16505141</pub-id><pub-id pub-id-type="pmcid">PMC2118242</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boscardin</surname><given-names>SB</given-names></name><name name-style="western"><surname>Hafalla</surname><given-names>JC</given-names></name><name name-style="western"><surname>Masilamani</surname><given-names>RF</given-names></name><name name-style="western"><surname>Kamphorst</surname><given-names>AO</given-names></name><name name-style="western"><surname>Zebroski</surname><given-names>HA</given-names></name><name name-style="western"><surname>Rai</surname><given-names>U</given-names></name><etal/></person-group><article-title>Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses</article-title>. <source>J Exp Med</source> (<year>2006</year>) <volume>203</volume>(<issue>3</issue>):<fpage>599</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20051639</pub-id><pub-id pub-id-type="pmid">16505139</pub-id><pub-id pub-id-type="pmcid">PMC2118236</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifaz</surname><given-names>LC</given-names></name><name name-style="western"><surname>Bonnyay</surname><given-names>DP</given-names></name><name name-style="western"><surname>Charalambous</surname><given-names>A</given-names></name><name name-style="western"><surname>Darguste</surname><given-names>DI</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S</given-names></name><name name-style="western"><surname>Soares</surname><given-names>H</given-names></name><etal/></person-group><article-title>In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>199</volume>(<issue>6</issue>):<fpage>815</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20032220</pub-id><pub-id pub-id-type="pmid">15024047</pub-id><pub-id pub-id-type="pmcid">PMC2212731</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckman</surname><given-names>RA</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>HM</given-names></name></person-group>. <article-title>Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors</article-title>. <source>Cancer</source> (<year>2007</year>) <volume>109</volume>(<issue>2</issue>):<fpage>170</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/cncr.22402</pub-id><pub-id pub-id-type="pmid">17154393</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granucci</surname><given-names>F</given-names></name><name name-style="western"><surname>Prosperi</surname><given-names>D</given-names></name></person-group><article-title>Nanoparticles: &#8220;magic bullets&#8221; for targeting the immune system</article-title>. <source>Semin Immunol</source> (<year>2017</year>) <volume>34</volume>:<fpage>1</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1016/j.smim.2017.10.002</pub-id><pub-id pub-id-type="pmid">29173493</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prosperi</surname><given-names>D</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>M</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Granucci</surname><given-names>F</given-names></name></person-group>. <article-title>Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases</article-title>. <source>Semin Immunol</source> (<year>2017</year>) <volume>34</volume>:<fpage>61</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.smim.2017.08.010</pub-id><pub-id pub-id-type="pmid">28855088</pub-id><pub-id pub-id-type="pmcid">PMC5705526</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boraschi</surname><given-names>D</given-names></name><name name-style="western"><surname>Italiani</surname><given-names>P</given-names></name><name name-style="western"><surname>Palomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Decuzzi</surname><given-names>P</given-names></name><name name-style="western"><surname>Duschl</surname><given-names>A</given-names></name><name name-style="western"><surname>Fadeel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Nanoparticles and innate immunity: new perspectives on host defence</article-title>. <source>Semin Immunol</source> (<year>2017</year>) <volume>34</volume>:<fpage>33</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1016/j.smim.2017.08.013</pub-id><pub-id pub-id-type="pmid">28869063</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantoff</surname><given-names>PW</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Blumenstein</surname><given-names>BA</given-names></name><name name-style="western"><surname>Glode</surname><given-names>LM</given-names></name><name name-style="western"><surname>Bilhartz</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wyand</surname><given-names>M</given-names></name><etal/></person-group><article-title>Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer</article-title>. <source>J Clin Oncol</source> (<year>2010</year>) <volume>28</volume>(<issue>7</issue>):<fpage>1099</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="doi">10.1200/JCO.2009.25.0597</pub-id><pub-id pub-id-type="pmid">20100959</pub-id><pub-id pub-id-type="pmcid">PMC2834462</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A novel antigen delivery system induces strong humoral and CTL immune responses</article-title>. <source>Biomaterials</source> (<year>2017</year>) <volume>134</volume>:<fpage>51</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.04.035</pub-id><pub-id pub-id-type="pmid">28456076</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rincon-Restrepo</surname><given-names>M</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>A</given-names></name><name name-style="western"><surname>Hauert</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonner</surname><given-names>DK</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>EA</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Vaccine nanocarriers: coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses</article-title>. <source>Biomaterials</source> (<year>2017</year>) <volume>132</volume>:<fpage>48</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.03.047</pub-id><pub-id pub-id-type="pmid">28407494</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name><name name-style="western"><surname>Noh</surname><given-names>YW</given-names></name><name name-style="western"><surname>Kang</surname><given-names>TH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Um</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity</article-title>. <source>Biomaterials</source> (<year>2017</year>) <volume>130</volume>:<fpage>56</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.03.034</pub-id><pub-id pub-id-type="pmid">28364631</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waeckerle-Men</surname><given-names>Y</given-names></name><name name-style="western"><surname>Groettrup</surname><given-names>M</given-names></name></person-group>. <article-title>PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines</article-title>. <source>Adv Drug Deliv Rev</source> (<year>2005</year>) <volume>57</volume>:<fpage>475</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.addr.2004.09.007</pub-id><pub-id pub-id-type="pmid">15560953</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maji</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazumder</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>ST</given-names></name><name name-style="western"><surname>Sabur</surname><given-names>A</given-names></name><name name-style="western"><surname>Shadab</surname><given-names>M</given-names></name><etal/></person-group><article-title>A lipid based antigen delivery system efficiently facilitates MHC class-I antigen presentation in dendritic cells to stimulate CD8+T cells</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1038/srep27206</pub-id><pub-id pub-id-type="pmid">27251373</pub-id><pub-id pub-id-type="pmcid">PMC4890172</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachem</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#252;ttler</surname><given-names>S</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>E</given-names></name><name name-style="western"><surname>Ebstein</surname><given-names>F</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name><name name-style="western"><surname>Tannert</surname><given-names>A</given-names></name><etal/></person-group><article-title>Superior antigen cross-presentation and XCR1 expression define human CD11c <sup>+</sup> CD141 <sup>+</sup> cells as homologues of mouse CD8 <sup>+</sup> dendritic cells</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>(<issue>6</issue>):<fpage>1273</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20100348</pub-id><pub-id pub-id-type="pmid">20479115</pub-id><pub-id pub-id-type="pmcid">PMC2882837</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huysamen</surname><given-names>C</given-names></name><name name-style="western"><surname>Willment</surname><given-names>JA</given-names></name><name name-style="western"><surname>Dennehy</surname><given-names>KM</given-names></name><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name></person-group>. <article-title>CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes</article-title>. <source>J Biol Chem</source> (<year>2008</year>) <volume>283</volume>(<issue>24</issue>):<fpage>16693</fpage>&#8211;<lpage>701</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M709923200</pub-id><pub-id pub-id-type="pmid">18408006</pub-id><pub-id pub-id-type="pmcid">PMC2562446</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulin</surname><given-names>LF</given-names></name><name name-style="western"><surname>Salio</surname><given-names>M</given-names></name><name name-style="western"><surname>Griessinger</surname><given-names>E</given-names></name><name name-style="western"><surname>Anjos-Afonso</surname><given-names>F</given-names></name><name name-style="western"><surname>Craciun</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Characterization of human DNGR-1 <sup>+</sup> BDCA3 <sup>+</sup> leukocytes as putative equivalents of mouse CD8&#945; <sup>+</sup> dendritic cells</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>(<issue>6</issue>):<fpage>1261</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20092618</pub-id><pub-id pub-id-type="pmid">20479117</pub-id><pub-id pub-id-type="pmcid">PMC2882845</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroczek</surname><given-names>RA</given-names></name><name name-style="western"><surname>Henn</surname><given-names>V</given-names></name></person-group>. <article-title>The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>3</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00014</pub-id><pub-id pub-id-type="pmid">22566900</pub-id><pub-id pub-id-type="pmcid">PMC3342032</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreibelt</surname><given-names>G</given-names></name><name name-style="western"><surname>Klinkenberg</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Tel</surname><given-names>J</given-names></name><name name-style="western"><surname>Kreutz</surname><given-names>M</given-names></name><etal/></person-group><article-title>The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>(<issue>10</issue>):<fpage>2284</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-08-373944</pub-id><pub-id pub-id-type="pmid">22234694</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>LC</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>AG</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>De Rose</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>45</volume>(<issue>3</issue>):<fpage>854</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201445127</pub-id><pub-id pub-id-type="pmid">25487143</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Kitsoulis</surname><given-names>S</given-names></name><name name-style="western"><surname>Teh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lo</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rizzitelli</surname><given-names>A</given-names></name><etal/></person-group><article-title>The dendritic cell subtype restricted C-type lectin Clec9A is a target for vaccine enhancement</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>(<issue>8</issue>):<fpage>3264</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2008-05-155176</pub-id><pub-id pub-id-type="pmid">18669894</pub-id><pub-id pub-id-type="pmcid">PMC2569177</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lahoud</surname><given-names>MH</given-names></name><name name-style="western"><surname>Ahmet</surname><given-names>F</given-names></name><name name-style="western"><surname>Kitsoulis</surname><given-names>S</given-names></name><name name-style="western"><surname>Wan</surname><given-names>SS</given-names></name><name name-style="western"><surname>Vremec</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>(<issue>2</issue>):<fpage>842</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1101176</pub-id><pub-id pub-id-type="pmid">21677141</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A</given-names></name><name name-style="western"><surname>Davey</surname><given-names>GM</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>SN</given-names></name><name name-style="western"><surname>Nutt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Zotos</surname><given-names>D</given-names></name><etal/></person-group><article-title>Targeting antigen to Clec9A primes follicular Th cell memory responses capable of robust recall</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>195</volume>(<issue>3</issue>):<fpage>1006</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1500767</pub-id><pub-id pub-id-type="pmid">26101322</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Light</surname><given-names>A</given-names></name><name name-style="western"><surname>Lahoud</surname><given-names>MH</given-names></name><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><name name-style="western"><surname>Tarlinton</surname><given-names>DM</given-names></name><name name-style="western"><surname>Shortman</surname><given-names>K</given-names></name></person-group>. <article-title>Evolution of B cell responses to Clec9A-targeted antigen</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>(<issue>10</issue>):<fpage>4919</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1301947</pub-id><pub-id pub-id-type="pmid">24123689</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tullett</surname><given-names>KM</given-names></name><name name-style="western"><surname>Leal Rojas</surname><given-names>IM</given-names></name><name name-style="western"><surname>Minoda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>PS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JG</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><etal/></person-group><article-title>Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition</article-title>. <source>JCI Insight</source> (<year>2016</year>) <volume>1</volume>(<issue>7</issue>):<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1172/jci.insight.87102</pub-id><pub-id pub-id-type="pmid">27699265</pub-id><pub-id pub-id-type="pmcid">PMC5033826</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>HY</given-names></name><name name-style="western"><surname>Tan</surname><given-names>PS</given-names></name><name name-style="western"><surname>Kavishna</surname><given-names>R</given-names></name><name name-style="western"><surname>Ker</surname><given-names>A</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CEZ</given-names></name><etal/></person-group><article-title>Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells</article-title>. <source>NPJ Vaccines</source> (<year>2017</year>) <volume>2</volume>(<issue>1</issue>):<fpage>31</fpage>.<pub-id pub-id-type="doi">10.1038/s41541-017-0033-5</pub-id><pub-id pub-id-type="pmid">29263886</pub-id><pub-id pub-id-type="pmcid">PMC5674066</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sancho</surname><given-names>D</given-names></name><name name-style="western"><surname>Mour&#227;o-S&#225;</surname><given-names>D</given-names></name><name name-style="western"><surname>Joffre</surname><given-names>OP</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>O</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>NC</given-names></name><name name-style="western"><surname>Pennington</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin</article-title>. <source>J Clin Invest</source> (<year>2008</year>) <volume>118</volume>(<issue>6</issue>):<fpage>2098</fpage>&#8211;<lpage>110</lpage>.<pub-id pub-id-type="doi">10.1172/JCI34584</pub-id><pub-id pub-id-type="pmid">18497879</pub-id><pub-id pub-id-type="pmcid">PMC2391066</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Swiggard</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Heufler</surname><given-names>C</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>A</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name><etal/></person-group><article-title>The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing</article-title>. <source>Nature</source> (<year>1995</year>) <volume>375</volume>(<issue>6527</issue>):<fpage>151</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/375151a0</pub-id><pub-id pub-id-type="pmid">7753172</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrimpton</surname><given-names>RE</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M</given-names></name><name name-style="western"><surname>Morel</surname><given-names>AS</given-names></name><name name-style="western"><surname>Eren</surname><given-names>E</given-names></name><name name-style="western"><surname>Hue</surname><given-names>SS</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>MA</given-names></name></person-group>. <article-title>CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self</article-title>. <source>Mol Immunol</source> (<year>2009</year>) <volume>46</volume>(<issue>6</issue>):<fpage>1229</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2008.11.016</pub-id><pub-id pub-id-type="pmid">19135256</pub-id><pub-id pub-id-type="pmcid">PMC2680960</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>M</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ross</surname><given-names>IL</given-names></name><name name-style="western"><surname>Vuckovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Expression of human DEC-205 (CD205) multilectin receptor on leukocytes</article-title>. <source>Int Immunol</source> (<year>2006</year>) <volume>18</volume>(<issue>6</issue>):<fpage>857</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1093/intimm/dxl022</pub-id><pub-id pub-id-type="pmid">16581822</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahnke</surname><given-names>K</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Sepulveda</surname><given-names>H</given-names></name><name name-style="western"><surname>Swain</surname><given-names>SL</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>M</given-names></name><etal/></person-group><article-title>The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II &#8211; positive lysosomal compartments</article-title>. <source>J Cell Biol</source> (<year>2000</year>) <volume>151</volume>(<issue>3</issue>):<fpage>673</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1083/jcb.151.3.673</pub-id><pub-id pub-id-type="pmid">11062267</pub-id><pub-id pub-id-type="pmcid">PMC2185598</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S</given-names></name><name name-style="western"><surname>Maric</surname><given-names>S</given-names></name><name name-style="western"><surname>Misulovin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pack</surname><given-names>M</given-names></name><name name-style="western"><surname>Mahnke</surname><given-names>K</given-names></name><etal/></person-group><article-title>A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells</article-title>. <source>Hum Immunol</source> (<year>2000</year>) <volume>61</volume>(<issue>8</issue>):<fpage>729</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1016/S0198-8859(00)00144-0</pub-id><pub-id pub-id-type="pmid">10980384</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifaz</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonnyay</surname><given-names>D</given-names></name><name name-style="western"><surname>Mahnke</surname><given-names>K</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>M</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name></person-group>. <article-title>Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8 <sup>+</sup> T cell tolerance</article-title>. <source>J Exp Med</source> (<year>2002</year>) <volume>196</volume>(<issue>12</issue>):<fpage>1627</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20021598</pub-id><pub-id pub-id-type="pmid">12486105</pub-id><pub-id pub-id-type="pmcid">PMC2196060</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tel</surname><given-names>J</given-names></name><name name-style="western"><surname>Benitez-Ribas</surname><given-names>D</given-names></name><name name-style="western"><surname>Hoosemans</surname><given-names>S</given-names></name><name name-style="western"><surname>Cambi</surname><given-names>A</given-names></name><name name-style="western"><surname>Adema</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>CG</given-names></name><etal/></person-group><article-title>DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells</article-title>. <source>Eur J Immunol</source> (<year>2011</year>) <volume>41</volume>(<issue>4</issue>):<fpage>1014</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201040790</pub-id><pub-id pub-id-type="pmid">21413003</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozzacco</surname><given-names>L</given-names></name><name name-style="western"><surname>Trumpfheller</surname><given-names>C</given-names></name><name name-style="western"><surname>Siegal</surname><given-names>FP</given-names></name><name name-style="western"><surname>Mehandru</surname><given-names>S</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>M</given-names></name><etal/></person-group><article-title>DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>(<issue>4</issue>):<fpage>1289</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0610383104</pub-id><pub-id pub-id-type="pmid">17229838</pub-id><pub-id pub-id-type="pmcid">PMC1783096</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartorius</surname><given-names>R</given-names></name><name name-style="western"><surname>D&#8217;Apice</surname><given-names>L</given-names></name><name name-style="western"><surname>Trovato</surname><given-names>M</given-names></name><name name-style="western"><surname>Cuccaro</surname><given-names>F</given-names></name><name name-style="western"><surname>Costa</surname><given-names>V</given-names></name><name name-style="western"><surname>De Leo</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response</article-title>. <source>EMBO Mol Med</source> (<year>2015</year>) <volume>7</volume>(<issue>7</issue>):<fpage>973</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.15252/emmm.201404525</pub-id><pub-id pub-id-type="pmid">25888235</pub-id><pub-id pub-id-type="pmcid">PMC4520660</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartorius</surname><given-names>R</given-names></name><name name-style="western"><surname>Bettua</surname><given-names>C</given-names></name><name name-style="western"><surname>D&#8217;Apice</surname><given-names>L</given-names></name><name name-style="western"><surname>Caivano</surname><given-names>A</given-names></name><name name-style="western"><surname>Trovato</surname><given-names>M</given-names></name><name name-style="western"><surname>Russo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants</article-title>. <source>Eur J Immunol</source> (<year>2011</year>) <volume>41</volume>(<issue>9</issue>):<fpage>2573</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201141526</pub-id><pub-id pub-id-type="pmid">21688262</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caminschi</surname><given-names>I</given-names></name><name name-style="western"><surname>Meuter</surname><given-names>S</given-names></name><name name-style="western"><surname>Heath</surname><given-names>WR</given-names></name></person-group>. <article-title>DEC-205 is a cell surface receptor for CpG oligonucleotides</article-title>. <source>Oncoimmunology</source> (<year>2013</year>) <volume>2</volume>(<issue>3</issue>):<fpage>e23128</fpage>.<pub-id pub-id-type="doi">10.4161/onci.23128</pub-id><pub-id pub-id-type="pmid">23802064</pub-id><pub-id pub-id-type="pmcid">PMC3661149</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>T</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>FU</given-names></name><name name-style="western"><surname>Wieland</surname><given-names>F</given-names></name></person-group>. <article-title>CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes</article-title>. <source>J Cell Biol</source> (<year>2002</year>) <volume>158</volume>(<issue>7</issue>):<fpage>1277</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1083/jcb.200208083</pub-id><pub-id pub-id-type="pmid">12356871</pub-id><pub-id pub-id-type="pmcid">PMC2173242</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schjetne</surname><given-names>KW</given-names></name><name name-style="western"><surname>Fredriksen</surname><given-names>AB</given-names></name><name name-style="western"><surname>Bogen</surname><given-names>B</given-names></name></person-group>. <article-title>Delivery of antigen to CD40 induces protective immune responses against tumors</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>7</issue>):<fpage>4169</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.7.4169</pub-id><pub-id pub-id-type="pmid">17371973</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination</article-title>. <source>J Gene Med</source> (<year>2010</year>) <volume>12</volume>(<issue>6</issue>):<fpage>97</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="doi">10.1002/jgm.1412</pub-id><pub-id pub-id-type="pmid">19950201</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zurawski</surname><given-names>G</given-names></name><name name-style="western"><surname>Zurawski</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Akagawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S</given-names></name><etal/></person-group><article-title>A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40 hematology &amp; oncology</article-title>. <source>J Hematol Oncol</source> (<year>2015</year>) <volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1186/s13045-015-0131-7</pub-id><pub-id pub-id-type="pmid">25888530</pub-id><pub-id pub-id-type="pmcid">PMC4424584</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mingozzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Spreafico</surname><given-names>R</given-names></name><name name-style="western"><surname>Gorletta</surname><given-names>T</given-names></name><name name-style="western"><surname>Cigni</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Gioia</surname><given-names>M</given-names></name><name name-style="western"><surname>Caccia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prolonged contact with dendritic cells turns lymph node-resident NK cells into anti-tumor effectors</article-title>. <source>EMBO Mol Med</source> (<year>2016</year>) <volume>8</volume>(<issue>9</issue>):<fpage>1039</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.15252/emmm.201506164</pub-id><pub-id pub-id-type="pmid">27406819</pub-id><pub-id pub-id-type="pmcid">PMC5009809</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dissanayake</surname><given-names>D</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>K</given-names></name><name name-style="western"><surname>Tran</surname><given-names>MD</given-names></name><name name-style="western"><surname>Elford</surname><given-names>AR</given-names></name><name name-style="western"><surname>Millar</surname><given-names>DG</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>PS</given-names></name></person-group><article-title>Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>3</issue>):<fpage>e92380</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0092380</pub-id><pub-id pub-id-type="pmid">24647761</pub-id><pub-id pub-id-type="pmcid">PMC3960236</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijker</surname><given-names>MS</given-names></name><name name-style="western"><surname>van den Eeden</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Franken</surname><given-names>KL</given-names></name><name name-style="western"><surname>Melief</surname><given-names>CJ</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>SH</given-names></name><name name-style="western"><surname>Offringa</surname><given-names>R</given-names></name></person-group>. <article-title>Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation</article-title>. <source>Eur J Immunol</source> (<year>2008</year>) <volume>38</volume>:<fpage>1033</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200737995</pub-id><pub-id pub-id-type="pmid">18350546</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosalia</surname><given-names>RA</given-names></name><name name-style="western"><surname>Quakkelaar</surname><given-names>ED</given-names></name><name name-style="western"><surname>Redeker</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Camps</surname><given-names>M</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation</article-title>. <source>Eur J Immunol</source> (<year>2013</year>) <volume>43</volume>:<fpage>2554</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201343324</pub-id><pub-id pub-id-type="pmid">23836147</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenter</surname><given-names>GG</given-names></name><name name-style="western"><surname>Welters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>AR</given-names></name><name name-style="western"><surname>Lowik</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Berends-van der Meer</surname><given-names>DM</given-names></name><name name-style="western"><surname>Vloon</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia</article-title>. <source>N Engl J Med</source> (<year>2009</year>) <volume>361</volume>:<fpage>1838</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa0810097</pub-id><pub-id pub-id-type="pmid">19890126</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabbatini</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T</given-names></name><name name-style="western"><surname>Ferran</surname><given-names>L</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>E</given-names></name><name name-style="western"><surname>Sedrak</surname><given-names>C</given-names></name><name name-style="western"><surname>Tuballes</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase I trial of overlapping long peptides from a tumor self- antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>:<fpage>6497</fpage>&#8211;<lpage>509</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2189</pub-id><pub-id pub-id-type="pmid">23032745</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeestraten</surname><given-names>EC</given-names></name><name name-style="western"><surname>Speetjens</surname><given-names>FM</given-names></name><name name-style="western"><surname>Welters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Saadatmand</surname><given-names>S</given-names></name><name name-style="western"><surname>Stynenbosch</surname><given-names>LF</given-names></name><name name-style="western"><surname>Jongen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Addition of interferon-&#945; to the p53-SLP V vaccine results in increased production of interferon- c in vaccinated colorectal cancer patients: a phase I/II clinical trial</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>132</volume>:<fpage>1581</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.27819</pub-id><pub-id pub-id-type="pmid">22948952</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speetjens</surname><given-names>FM</given-names></name><name name-style="western"><surname>Kuppen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Welters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Essahsah</surname><given-names>F</given-names></name><name name-style="western"><surname>Voet van den Brink</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lantrua</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients T reated for metastatic colorectal cancer</article-title>. <source>Clin Cancer Res</source> (<year>2009</year>) <volume>15</volume>(<issue>3</issue>):<fpage>1086</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2227</pub-id><pub-id pub-id-type="pmid">19188184</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarntzen</surname><given-names>EH</given-names></name><name name-style="western"><surname>Schreibelt</surname><given-names>G</given-names></name><name name-style="western"><surname>Bol</surname><given-names>K</given-names></name><name name-style="western"><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Croockewit</surname><given-names>AJ</given-names></name><name name-style="western"><surname>de Wilt</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients</article-title>. <source>Clin Cancer Res</source> (<year>2012</year>) <volume>18</volume>(<issue>19</issue>):<fpage>5460</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3368</pub-id><pub-id pub-id-type="pmid">22896657</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryson</surname><given-names>PD</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Truong</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name></person-group>. <article-title>Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>(<issue>43</issue>):<fpage>5842</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.017</pub-id><pub-id pub-id-type="pmid">28916248</pub-id><pub-id pub-id-type="pmcid">PMC5624555</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>TN</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>RD</given-names></name></person-group>. <article-title>Neoantigens in cancer immunotherapy</article-title>. <source>Science</source> (<year>2015</year>) <volume>348</volume>(<issue>6230</issue>):<fpage>69</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanyi</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bobisse</surname><given-names>S</given-names></name><name name-style="western"><surname>Ophir</surname><given-names>E</given-names></name><name name-style="western"><surname>Tuyaerts</surname><given-names>S</given-names></name><name name-style="western"><surname>Roberti</surname><given-names>A</given-names></name><name name-style="western"><surname>Genolet</surname><given-names>R</given-names></name><etal/></person-group><article-title>Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer</article-title>. <source>Sci Transl Med</source> (<year>2018</year>) <volume>5931</volume>(<issue>April</issue>):<fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.aao5931</pub-id><pub-id pub-id-type="pmid">29643231</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M</given-names></name><name name-style="western"><surname>Kloke</surname><given-names>BP</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title>. <source>Nature</source> (<year>2017</year>) <volume>547</volume>(<issue>7662</issue>):<fpage>222</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="pmid">28678784</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Bozym</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title>. <source>Nature</source> (<year>2017</year>) <volume>547</volume>(<issue>7662</issue>):<fpage>217</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1038/nature22991</pub-id><pub-id pub-id-type="pmid">28678778</pub-id><pub-id pub-id-type="pmcid">PMC5577644</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laxmanan</surname><given-names>S</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>SW</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E</given-names></name><name name-style="western"><surname>Lau</surname><given-names>JS</given-names></name><name name-style="western"><surname>David</surname><given-names>M</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>D</given-names></name></person-group>. <article-title>Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2005</year>) <volume>334</volume>(<issue>1</issue>):<fpage>193</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbrc.2005.06.065</pub-id><pub-id pub-id-type="pmid">16002046</pub-id><pub-id pub-id-type="pmcid">PMC4495768</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimura</surname><given-names>K</given-names></name><name name-style="western"><surname>Kono</surname><given-names>K</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H</given-names></name></person-group>. <article-title>Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2</article-title>. <source>Cancer Immunol Immunother</source> (<year>2007</year>) <volume>56</volume>:<fpage>761</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1007/s00262-006-0234-7</pub-id><pub-id pub-id-type="pmid">17086423</pub-id><pub-id pub-id-type="pmcid">PMC11030780</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baghdadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Endo</surname><given-names>H</given-names></name><name name-style="western"><surname>Takano</surname><given-names>A</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Kameda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wada</surname><given-names>H</given-names></name><etal/></person-group><article-title>High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>418</fpage>.<pub-id pub-id-type="doi">10.1038/s41598-017-18796-8</pub-id><pub-id pub-id-type="pmid">29323162</pub-id><pub-id pub-id-type="pmcid">PMC5765132</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>JY</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q-D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Tumor-derived TGF-&#946; reduces the efficacy of dendritic cell/tumor fusion vaccine</article-title>. <source>J Immunol</source> (<year>2018</year>) <volume>170</volume>:<fpage>3806</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.170.7.3806</pub-id><pub-id pub-id-type="pmid">12646647</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name></person-group>. <article-title>Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>(<issue>10</issue>):<fpage>e0139598</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0139598</pub-id><pub-id pub-id-type="pmid">26440936</pub-id><pub-id pub-id-type="pmcid">PMC4595202</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oft</surname><given-names>M</given-names></name></person-group>. <article-title>IL-10: master switch from tumor-promoting in flammation to antitumor immunity</article-title>. <source>Cancer Immunol Res</source> (<year>2014</year>) <volume>2</volume>:<fpage>194</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0214</pub-id><pub-id pub-id-type="pmid">24778315</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verron&#232;se</surname><given-names>E</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>A</given-names></name><name name-style="western"><surname>Valladeau-Guillemond</surname><given-names>J</given-names></name><name name-style="western"><surname>Garin</surname><given-names>G</given-names></name><name name-style="western"><surname>Guillemaut</surname><given-names>S</given-names></name><name name-style="western"><surname>Tredan</surname><given-names>O</given-names></name><etal/></person-group><article-title>Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay</article-title>. <source>Oncoimmunology</source> (<year>2016</year>) <volume>5</volume>(<issue>3</issue>):<fpage>e1100791</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1100791</pub-id><pub-id pub-id-type="pmid">27141361</pub-id><pub-id pub-id-type="pmcid">PMC4839376</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imai</surname><given-names>K</given-names></name><name name-style="western"><surname>Minamiya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Koyota</surname><given-names>S</given-names></name><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of dendritic cell migration by transforming growth factor-b 1 increases tumor-draining lymph node metastasis</article-title>. <source>J Exp Clin Cancer Res</source> (<year>2012</year>) <volume>31</volume>(<issue>3</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1186/1756-9966-31-3</pub-id><pub-id pub-id-type="pmid">22233831</pub-id><pub-id pub-id-type="pmcid">PMC3298529</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreibelt</surname><given-names>G</given-names></name><name name-style="western"><surname>Bol</surname><given-names>KF</given-names></name><name name-style="western"><surname>Westdorp</surname><given-names>H</given-names></name><name name-style="western"><surname>Wimmers</surname><given-names>F</given-names></name><name name-style="western"><surname>Aarntzen</surname><given-names>EH</given-names></name><name name-style="western"><surname>Duiveman-de Boer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells</article-title>. <source>Clin Cancer Res</source> (<year>2016</year>) <volume>22</volume>(<issue>9</issue>):<fpage>2155</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2205</pub-id><pub-id pub-id-type="pmid">26712687</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anandasabapathy</surname><given-names>N</given-names></name><name name-style="western"><surname>Feder</surname><given-names>R</given-names></name><name name-style="western"><surname>Mollah</surname><given-names>S</given-names></name><name name-style="western"><surname>Tse</surname><given-names>SW</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>MP</given-names></name><name name-style="western"><surname>Mehandru</surname><given-names>S</given-names></name><etal/></person-group><article-title>Classical Flt3L-dependent dendritic cells control immunity to protein vaccine</article-title>. <source>J Exp Med</source> (<year>2014</year>) <volume>211</volume>(<issue>9</issue>):<fpage>1875</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20131397</pub-id><pub-id pub-id-type="pmid">25135299</pub-id><pub-id pub-id-type="pmcid">PMC4144735</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreiter</surname><given-names>S</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M</given-names></name><name name-style="western"><surname>Selmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Diekmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Attig</surname><given-names>S</given-names></name><name name-style="western"><surname>H&#252;semann</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines</article-title>. <source>Cancer Res</source> (<year>2011</year>) <volume>71</volume>(<issue>19</issue>):<fpage>6132</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0291</pub-id><pub-id pub-id-type="pmid">21816907</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Shibayama</surname><given-names>C</given-names></name><name name-style="western"><surname>Gil-Cruz</surname><given-names>C</given-names></name><name name-style="western"><surname>Nussbacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Allg&#228;uer</surname><given-names>E</given-names></name><name name-style="western"><surname>Cervantes-Barragan</surname><given-names>L</given-names></name><name name-style="western"><surname>Z&#252;st</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>(<issue>11</issue>):<fpage>e81442</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0081442</pub-id><pub-id pub-id-type="pmid">24312302</pub-id><pub-id pub-id-type="pmcid">PMC3842931</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonios</surname><given-names>JP</given-names></name><name name-style="western"><surname>Soto</surname><given-names>H</given-names></name><name name-style="western"><surname>Everson</surname><given-names>RG</given-names></name><name name-style="western"><surname>Orpilla</surname><given-names>J</given-names></name><name name-style="western"><surname>Moughon</surname><given-names>D</given-names></name><name name-style="western"><surname>Shin</surname><given-names>N</given-names></name><etal/></person-group><article-title>PD-1 blockade enhances the vaccination-induced immune response in glioma</article-title>. <source>JCI Insight</source> (<year>2016</year>) <volume>1</volume>(<issue>10</issue>):<fpage>e87059</fpage>.<pub-id pub-id-type="doi">10.1172/jci.insight.87059</pub-id><pub-id pub-id-type="pmid">27453950</pub-id><pub-id pub-id-type="pmcid">PMC4951098</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Koropatnick</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Velenosi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ling</surname><given-names>H</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><etal/></person-group><article-title>Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>132</volume>:<fpage>967</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.27710</pub-id><pub-id pub-id-type="pmid">22870862</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>D</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AVS</given-names></name></person-group>. <article-title>Searching for the human genetic factors standing in the way of universally effective vaccines</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source> (<year>2015</year>) <volume>370</volume>(<issue>1671</issue>):<fpage>20140341</fpage>&#8211;<lpage>20140341</lpage>.<pub-id pub-id-type="doi">10.1098/rstb.2014.0341</pub-id><pub-id pub-id-type="pmid">25964463</pub-id><pub-id pub-id-type="pmcid">PMC4527396</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Schwartzberg</surname><given-names>PL</given-names></name><name name-style="western"><surname>Kotliarov</surname><given-names>Y</given-names></name><name name-style="western"><surname>Biancotto</surname><given-names>A</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Global analyses of human immune variation reveal baseline predictors of postvaccination responses</article-title>. <source>Cell</source> (<year>2014</year>) <volume>157</volume>(<issue>2</issue>):<fpage>499</fpage>&#8211;<lpage>513</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2014.03.031</pub-id><pub-id pub-id-type="pmid">24725414</pub-id><pub-id pub-id-type="pmcid">PMC4139290</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>